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ABSTRACT 
 
 
   Anaplastic thyroid carcinoma (ATC) represents one of the most lethal human 
neoplasia with a survival time of 2-6 months after diagnosis and it is refractory 
to current available therapies such as chemo- and radiotherapy.  
For this reason it is necessary to find new therapeutic approaches and the use of 
oncolytic viruses represents a promising strategy.  
In this study I have evaluated a therapeutic approach based on dl922-947, an 
oncolytic adenovirus bearing a deletion of 24 bp in E1A-Conserved Region 2 
(CR2). This adenoviral mutant is unable to bind the product of Rb gene 
therefore replicates only in neoplastic cells without an intact G1-S checkpoint. 
This checkpoint is lost in almost all human neoplasias and also in anaplastic 
thyroid carcinoma. Here I have reported that dl922-947 induces cell death in a 
panel of human anaplastic thyroid cell lines and the in vivo experiments, 
against ATC tumour xenografts, show an improved response rates compared 
with the adenoviruses dl1520. I have also demonstrated that dl922/947 has a 
higher replication efficiency compared with the adenoviruses dl1520.  
To enhance the antineoplastic effects of dl922-947, I have evaluated the effects 
of a combined treatment with an anti VEGF monoclonal antibody 
(Bevacizumab) and dl922-947 against ATC tumour xenografts. I have 
observed a significant reduction of tumour growth with respect to single 
treatments. Furthermore I have observed that the combined treatment enhances 
the viral distribution within the tumour mass and increases the viral replication.                 
These results suggest that dl922-947 may be a valid tool in the treatment of the 
anaplastic thyroid carcinoma and the combined treatment dl922-
947/Bevacizumab could represent a novel strategy to improve the delivery of 
oncolytic viruses into the tumours.  
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1. INTRODUCTION 
 
 
1.1 Oncolytic viruses in the treatment of cancer 
 
   The notion that viruses may be able to eradicate cancer has existed since the 
early 20th century (Sinkovics and Horvath  1993, Sinkovics and Horvath 2000, 
Southam and Moore 1952). Several viruses were tested both in experimental 
settings and in humans during the 1950s and 1960s. Among the first viruses to 
be used in a controlled fashion in clinical studies was a vaccine strain of rabies 
virus to treat 30 patients with melanomatosis, eight of whom showed tumour 
regression (Pack 1950). A few years later the oncolytic efficacy of adenovirus 
serotype type 4, was tested in humans (Southam CM et al. 1956), as well as the 
flavivirus West Nile virus (strain Egypt 101) (Southam and Moore 1952) and 
the paramyxoviruses mumps and Newcastle disease virus (NDV) (Asada 1974, 
Okuno et al. 1978). Also, many viruses were tested in animal models. For 
instance, bovine enterovirus showed efficient lysis of syngeneic tumours in 
immunocompetent mice (Taylor et al. 1971). Unfortunately all these 
approaches failed because of an insufficient knowledge about purification 
systems. Later in the 1990s, with the advent of modern biotechnology and the 
concept of gene therapy, interest in viruses as a treatment for cancer was 
rekindled, and today virotherapy is asserting itself as a formidable treatment 
option alongside surgery, chemo- and radiation therapy. 
There are many reasons that can explain the use of viruses in cancer therapy, in 
particular cancer cells are generous hosts for viruses, being preferred over other 
types of cells because of they may simultaneously lose critical components of 
the intracellular defence mechanisms and thus become fertile ground for the 
replication of many viruses. Oncolytic viruses are able to replicate only in 
cancer cells but not in normal cells and being mutated to be dependent on 
certain molecular defects in cancer cells they are called conditionally 
replicating (i.e. restricted to replicate only in permissive cells). For example, 
some adenoviral vectors have been deleted for the E1B gene in order to restrict 
their replication to cells in which the function of the p53 protein is impaired. 
As another example, herpes viruses lose the ability to infect non-dividing cells 
by deletion of the thymidine kinase gene, thereby forcing these viruses to 
prefer tumour cells over normal cells (Martuza 1991).  
Members from an increasing number of virus families are being considered for 
cancer gene therapy. Some of these viruses are reported in table below (table 1). 
In the following some further details will be given only about the ones used in 
clinical trials. 
 
 
 
 
 
 6
Table 1: Oncolytic virus in cancer gene therapy 
 
Virus Phase of development 
Herpes  Simplex Virus Phase I in glioma patients  
Poliomavirus Tested in preclinical models 
Poxvirus Phase I in refractory and/or current  
melanoma patients  
 
Reovirus Phase I in glioma and  
melanoma patients  
Newcastle disease virus Phase I in advanced solid  
cancer patients  
 
Rhabdovirus Tested in preclinical models 
Coronavirus Tested in preclinical models 
Picornavirus Tested in preclinical models 
Retrovirus Tested in preclinical models 
Adenovirus Phase I/II/III  
 
In this table a group of the most important oncolytic viruses is reported. Oncolytic viruses that 
are used in different phase of clinical trials are indicated in blue. 
 
 
 
1.1.1 Herpes simplex virus   
 
   HSV-1 is an enveloped, double-stranded DNA virus with a genome size of 
approximately 152 kb. There are two general strategies that are employed to 
target HSV-1 replication to cancer cells. The first involves deletion or 
inactivation of viral genes that are essential for viral replication in normal cells 
but dispensable in tumour cells, such as HSV-tk, ribonucleotide reductase, and 
γ134.5. The initial HSV-1 mutant studied for tumour-selective replication, 
dlsptk, contains a 360-bp deletion within HSV-tk, and it was used to treat 
malignant gliomas in rodents (Martuza 1991). Accordingly, dlsptk replicates 
well in cultured tumour cells and induces significant growth inhibition of 
human U87 gliomas growing in the brains of nude mice. However, this HSV-1 
mutant has not been examined in clinical trials because it produces 
neurotoxicity at higher titers, and it is resistant to the antiviral agents acyclovir 
and ganciclovir by virtue of its disrupted HSV-tk gene. Investigators looked 
instead at developing HSV-1 mutants that maintain sensitivity to acyclovir and 
ganciclovir and that exhibit less neurovirulence by deletion of the γ134.5 gene. 
One such γ134.5-null mutant is G207 (MediGene, Inc.; San Diego, CA) which 
exhibits tumour-cell-specific replication and antitumour efficacy in both in 
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vitro and in vivo models of malignant glioma (Mineta 1995) and a study of a 
phase I was conducted in patients with glioma (Shah 2003). 
 
 
 
1.1.2 Poxvirus  
 
   Poxviruses are large, enveloped, dsDNA viruses with a complex genome 
harbouring multiple immune-modulating genes. The most commonly used 
poxvirus in cancer targeting is vaccinia virus (VV). Vaccinia virus has tropism 
for human cells and its high immunogenicity. Three properties of vaccinia 
virus are being used to develop the virus as a cancer therapy: (1) vaccinia virus 
has a high efficiency of infection, it replicates in the cytoplasm without 
chromosomal integration, and the 200 kb genome allows the insertion of a 
large amount of recombinant DNA without losing infectivity; (2) to develop 
cancer vaccines, the immunostimulatory properties of the virus are being 
harnessed to incite an immune response against cancer cells; (3) to develop an 
oncolytic virus, replication conditional viral mutants are being constructed to 
target specific cancer types. Vaccina virus was used in preclinical and phase I 
trials. Wild-type vaccinia virus does not selectively infect cancer cells. The 
virus requires modification to be made replication conditional. One strategy is 
to delete the viral TK gene. While the viral TK gene is necessary for infectivity 
in normal cells that possess small concentrations of intracellular nucleotide 
pools, it is not necessary in cancer cells (Mastrangelo 1999) which possess 
relatively high concentrations of intracellular nucleotides. Another novel vector 
involved replacing the viral TK gene with the gene for GM-CSF, creating a 
mutant vaccinia virus capable of selectively infecting melanoma cells, and 
inducing an antitumour immune response. This virus has been administered 
intralesionally in a phase I clinical trial involving patients with refractory 
and/or recurrent melanoma. Injected lesions contained an active inflammatory 
response and demonstrable viral replication (Mastrangelo 1999). 
 
 
 
1.1.3 Reovirus   
 
  Reovirus is a ubiquitous, nonenveloped double-stranded RNA virus with 
minimal pathogenicity in humans. Infections in humans are generally mild and 
restricted to the respiratory and gastrointestinal tracts. It was known that 
reovirus exhibited preferential cytotoxicity for transformed cells compared 
with normal cells (Hashiro et al. 1977, Duncan et al. 1978). Given the facts that 
reovirus exhibits preferential replication in cells with an activated ras 
signalling pathway and that some 30% or more of all human tumours possess 
an activating mutation of ras, reovirus appears to be an ideal oncolytic agent. 
Coffey et al. (1998) examined the efficacy of reovirus against flank tumours 
 8
established from v-erbB-transformed NIH 3T3 cells and human U87 
glioblastoma cells, which overexpress the platelet-derived growth factor 
receptor and thus have an activated ras pathway. A single intratumoural 
injection of 1 × 107 plaque forming units (pfu) of reovirus resulted in tumour 
regression in 65%-80% of mice. The virus also proved effective in treatment of 
tumours established from ras-transformed C3H-10T1/2 cells in 
immunocompetent C3H mice, and pre-existing immunity to reovirus did not 
abrogate the oncolytic effect. More recently, data were presented that 
intravenous administration of reovirus is effective in reducing tumour burden 
and prolonging survival of mice bearing Lewis lung carcinoma metastases 
(Hirasawa 2001) and a study of a phase I was conducted in patients with 
glioma and melanoma. 
 
 
 
1.1.4 Newcastle disease virus  
 
   NDV is a chicken paramyxovirus and an enveloped negative-stranded RNA 
virus. The virus is not pathogenic to humans and has been extensively studied 
as an oncolytic agent in several different human tumour cell lines and tumour 
models (Reichard 1992 and Lorence 1994). The first report of activity with 
Newcastle virus involved one patient with cervical cancer. Cassel and Garrett 
(1965) injected virus (2.4 x 1012 virus particles) directly into the tumour and 
demonstrated intratumoural regression of the cancer both at the injection site 
and at a distant malignant lymph node. Investigators at Pro-Virus, Inc. 
(Gaithersburg, MD) have isolated a naturally attenuated strain of NDV, cloned 
by nonrecombinant methods, that exhibits a broad range of oncolytic activity 
against human tumours. This strain, designated PV701, is characterized by its 
in vitro potency, as a ratio of 1 pfu to 10,000 tumour cells results in at least 
50% lysis of sensitive tumour cell lines in 5 days. PV701 is also characterized 
by its tumour selectivity, as 80% of human cancer cell lines are two to four log 
orders more sensitive than normal human cells to PV701-mediated killing 
(Roberts et al. 2001). These encouraging preclinical data have led to the 
initiation of a phase I clinical trial of PV701 administered intravenously to 
patients with advanced solid cancers who failed conventional therapy (Pecora 
et al. 2002). 
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1.1.5 Adenovirus  
 
   Adenoviruses are the most widely used oncolytic viruses in cancer therapy 
and also the most widely described, moreover there is a great number of 
clinical trials in which these viruses are used. 
 
 
a) Biology of adenovirus 
 
   Adenovirus is a non-enveloped, 80-110 nm diameter virus presenting 
icosahedral symmetry. The 51 distinct serotypes of human adenovirus have 
been classified into six groups (A–F) based on sequence homology and their 
ability to agglutinate red blood cells (Shenk 1996). Most studies have been 
carried out on adenovirus serotype 2 (Ad2) and Ad5. Human adenoviruses 
contain a linear, double stranded DNA genome of 30-36 Kb. The hexon, 
penton base, and knobbed fiber, are the most important capsid proteins for gene 
delivery. Adenovirus infection occurs through binding of the adenoviral fiber 
to cellular receptors such as the coxsackie-adenovirus receptor (CAR) or 
integrins (Fig.1).  
 
Figure 1: Adsorption and entry of adenovirus into the cell 
Attachment of adenovirus to cell surface receptor (on the left) and receptor-mediated 
endocytosis (on the right). 
 
 
After the virus internalization through endocytosis the virus escapes the 
endosome and translocates to the nuclear pore complex, where the viral DNA 
is released into the nucleus and transcription begins. Transcription, replication 
and viral packaging take place in the nucleus of the infected cell. A complex 
series of splicing accompanies transcription, and genes are transcribed from 
both strands. Adenoviral transcription occurs in two phases: early and late 
(Fields et al. 1996) (Fig.2).  
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Figure 2: Adenoviral genome  
The early and late gene of viral life-cycle are represented 
 
 
During the early phase, the host cell is transformed into an efficient producer of 
the viral genome. The first gene that is transcribed in the viral genome is E1A. 
The adenovirus E1A protein is encoded by several alternatively spliced 
mRNAs, with the predominant forms being the 12S and 13S mRNAs (Heise et 
al. 2000). Two regions of conserved sequence among E1A proteins of different 
adenovirus types are conserved regions 1 and 2 (CR1 and CR2). CR1 and CR2 
contribute to E1A-induced cell cycle progression and transformation (Fueyo et 
al. 2000, Rodriguez et al. 1997). During infection, the primary mechanism by 
which E1A forces quiescent cells to actively cycle is by interfering with 
proteins of the retinoblastoma (Rb) pathway (Harlow et al. 1986, Moran 1993) 
and this interaction is mediated primarily by CR2. Rb acts as a tumour 
suppressor via binding to E2F, a transcriptional activator that promotes 
expression of genes necessary for driving the cell into S phase (Nevins 1995). 
The E1A product is able to sequester Rb and release repression of E2F, 
allowing it to activate its target genes. E1A proteins have also been shown to 
modulate the activity of p107 and p130, two members of the Rb family that are 
also involved in regulating cell cycle progression (Parreno et al. 2001). In 
addition to binding to Rb, E1A also binds to p300, an important nuclear 
integrator of diverse signalling pathways that possesses intrinsic histone 
acetyltransferase (HAT) activity and is implicated in the activation of genes 
that maintain cell differentiation and inhibit the cell cycle. p300 regulates and 
activates transcription by acetylating multiple other transcription factors, E2F 
and p53 being two important examples. E1A has been shown to repress 
directly the HAT activity of p300 and to inhibit p300-dependent transcription 
(Hamamori et al. 1999, Chakravarti et al. 1999). All these actions of E1A result 
in the accumulation of p53. p53 is a cellular growth suppressor that acts as a 
G1 checkpoint control and in response to viral challenge, p53 may induce a G1 
growth arrest by inducing genes such as the cyclin-dependent kinase inhibitor 
p21/WAF1/Cip1 gene (El-Deiry et al. 1993, Xiong et al. 1993) or apoptosis by 
3’ 
5’ 3’ 
5’ 
E1A 
E2A 
E2B 
E4 
E3 
E1B 
L1 L2 L3 L4 L5
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inducing genes such as bax1 (Miyashita and Reed 1995). However the 
induction of apoptosis is inhibited by the products of the E1B gene. The E1B 
transcription unit encodes two proteins, E1B-55kDa and E1B-19kDa. The 
E1B-19kDa protein is a functional homologue of the proto-oncogene-encoded 
Bcl-2 and prevents apoptosis by similar mechanisms (Debbas et al. 1993, Rao 
et al. 1992). The E1B-55kDa protein complexes with the amino-terminal end 
of p53 and inhibits its activity as a transcription factor (Kao et al. 1990, Yew 
and Berk 1992, Yew et al. 1994). It is thought that these mechanisms for 
inhibiting apoptosis keep the cell alive as long as possible in order to maximize 
viral yields (Rao et al., 1992). In addition to its antiapoptotic functions, the 
E1B-55KDa protein facilitates the transport of viral mRNAs to the cytoplasm 
during the late stages of infection (Pilder et al., 1986). 
The E2 region encodes proteins necessary for replication of the viral genome: 
DNA polymerase, preterminal protein, and the 72-kDa single-stranded DNA-
binding protein (De Jong et al. 2003). 
Products of the viral E3 region function to subvert the host immune response 
and allow persistence of infected cells. The immune system has evolved a 
number of mechanisms for destroying virus-infected cells, including cell lysis 
by cytotoxic T lymphocytes and activation of receptor-mediated apoptotic 
pathways by chemokines. 
The E4 transcription unit encodes a number of proteins that have been known 
to play a role in cell cycle control and regulation of DNA replication. 
The viral structural proteins and the proteins necessary for assembly of the 
virion are encoded by genes expressed during the late phase of viral replication. 
Once viral progeny assembly is complete, new viral particles are released by 
cytolysis.  
 
 
b) Methods to render cytolytic adenoviruses tumour specific 
 
   There are different ways in order to developing tumour specificity in 
oncolytic adenoviruses:  
- by placing viral genes that initiate viral replication under the control of 
promoter sequences that are active only in tumour cells  
- by the modification of viral coat proteins that function in host cell infection. 
- by altering viral genes that attenuate replication in normal tissue but not in 
tumour cells 
The first strategy concerns the regulation of viral replication via cellular 
promoters that are overactive in certain tumour cells, sometimes referred to as 
“tumour-specific” promoters (Fig.3). Certain tumour types, such as germ cell 
tumours, prostate cancer, and hepatocellular carcinoma, express proteins that 
are not normally present in the human body after fetal development. Certain 
oncolytic adenoviruses have been created to take advantage of the expression 
of these tumour markers or dependence on normally secreted hormones by 
placing the E1A gene under the control of the promoters derived from the 
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genes of interest. The oncolytic adenovirus AvE2a04i (Hallenbeck et al. 1999), 
was created to target α-fetoprotein (AFP)-expressing hepatocellular carcinoma 
by placing E1A under the control of the AFP gene promoter. CV706 targets 
prostate cancer by placing E1A under the control of a promoter derived from 
the prostate-specific antigen (PSA) gene (Rodriguez et al. 1997). AdhOC-E1 
targets prostate tumour cells by using a promoter derived from the osteocalcin 
gene (Matsubara et al. 2001, Hsieh et al. 2002), the product of which is also 
secreted by prostate tumour cells. One major limitation with the use of these 
tumour-activated promoters to regulate adenovirus replication is that they are 
not always active in all tumour types. In fact the transcriptional activity for the 
driving promoter must be conserved in the target tumour, therefore promoter 
driven oncolytic adenoviruses are often not active against poorly differentiate 
carcinomas. 
 
 
 
Figure 3: Use of cellular promoters to direct lytic viral replication to tumour cells  
The E1A gene (gray arrow) is placed under control of a promoter (dashed rectangle) that is 
preferentially overactive in a given tumour cell-type. This modification drives viral replication 
in tumour cells but not normal cells. 
 
The second strategy used to create oncolytic adenovirus is to alter the structural 
viral envelope proteins to retarget the virus to tumour cell surfaces and direct 
the virus away from its normal receptor (Fig.4). The attachment of 
adenoviruses to a cell is initiated by interaction of the knob domain of the viral 
fiber protein with cell surface proteins such as the coxsackie-adenovirus 
receptor (Bergelson et al. 1997, Tomko et al. 1997). After attachment, the Arg-
Gly-Asp (RGD) peptide sequence within the viral penton protein interacts with 
αvβ3 and αvβ5 integrins, which then leads to the internalization of the virus by 
receptor-mediated endocytosis. One modification is to incorporate the RGD 
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motif into the knob protein that normally binds to the CAR. By adding this 
motif to the knob protein, the oncolytic adenovirus can infect a broader range 
of tumour cells, because αvβ3/5 integrins are expressed on a majority of cells. 
Another strategy consists in fusion between ectodomain of CAR and epidermal 
growth factor in order to mediate adenovirus targeting to epidermal growth 
factor receptor-positive cells (Dmitriev et al. 2000). 
 
 
 
Figure 4: Targeting viral infection to tumour cells through alterations in viral-host cell 
interactions 
One modification is to incorporate the RGD motif into the knob protein that normally binds to 
the CAR (see extension on knob circle in virus on right). By adding this motif to the knob 
protein, the oncolytic adenovirus can infect a broader range of tumour cells, because αvβ3/5 
integrins are expressed on a majority of cells.  
 
 
The last and the most widely-used strategy consists in the creation of 
replication-conditional adenoviruses genetically modified such as dl1520 and 
dl922-947. 
Mutant adenovirus dl1520 (also known as ONYX-015) contains a deletion in 
the E1B gene, preventing the formation of a functional E1B-55kD protein. 
With this mutation, dl1520 was expected to replicate only in p53-deficient cells 
(Bischoff et al. 1996).  (Fig. 5).  
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Figure 5: Attenuating viral replication in normal cells but not tumour cells via gene 
mutation. 
For example, by altering a region of the E1B gene, the adenovirus can selectively replicate in 
p53-deficient (i.e. tumour) cells and leave p53- competent cells intact.  
 
 
However, more recent studies show that dl1520 was able to replicate in cells 
with a wild-type TP53 gene (Gallimore and Turnell 2001, Petit et al. 2002, 
Geoerger et al. 2002, Harada and Berk 1999, Rothmann et al. 1998, Hall et al. 
1998, Goodrum and Ornelles 1998). There are several explanations for these 
conflicting results. There are other proteins that affect p53 activity in cells, 
such as p14ARF and mdm2 (Bischoff et al. 1996, Yang et al. 2001, Ries et al. 
2000). p14ARF down-regulates mdm2, which is an ubiquitin ligase that 
stimulates p53 degradation. Cancer cells with a loss in p14ARF gene 
expression due to gene deletion or with overexpression of mdm2 after gene 
amplification will create a p53-null phenotype thereby allowing dl1520 
replication in tumours containing a wild-type TP53 gene. Another explanation 
involves the adenoviral E4orf6 gene product, which also binds to p53 and 
inhibits p53-mediated apoptosis, possibly allowing E1B-55kDa-deficient 
adenoviruses to replicate in cells with wild-type p53 (Aoyagi et al. 2003). In 
addition to its role in the degradation of p53, the E1B-55kDa protein has 
several other important late-phase functions. For example, E1B-55KDa 
mediates late-viral RNA transport and the loss of E1B-55KDa restricts the viral 
replication to tumour cells capable of taking over the RNA export function of 
the viral gene product (O’Shea et al. 2005).  
dl1520 has been used in conjunction with chemotherapeutic agents in clinical 
trials of a phase I/II with evidence for potential synergistic antitumour activity. 
(Post et al. 2003). And recent results from a phase III clinical trial have 
confirmed the ability of an oncolytic adenovirus (H101) bearing a E1B-55kDa 
gene deletion similar to that present in dl1520, to increase the response rate of 
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nasopharyngeal carcinoma in combination with cisplatin (Crompton and Kirn 
2007, Yu and Fang 2007). 
A second generation adenoviral mutant is dl922-947, which is an E1A mutant. 
dl922–947 has a  24-bp deletion in E1A Conserved Region 2 (CR2) therefore, 
is unable to induce progression from G1 into S-phase of quiescent cells. The 
G1-S checkpoint is critical for cell growth progression and is lost in almost all 
cancer cells as a result of mutations or deletions of the RB or CDKN2A genes, 
amplification and overexpression of Cyclin D, and amplification, 
overexpression or mutation of the CDK4 gene (Sherr 2000, Roussel 1999).  
The in vitro efficacy of dl922-947 was demonstrated in a range of a cancer cell 
lines and this efficacy exceeded that of adenovirus 5 wild-type (Ad5wt) and 
dl1520 (Heise et al. 2000). A similar adenovirus, Δ24, with the same deletion 
in E1A-CR2, has shown activity in preclinical models of glioma (Fueyo et al. 
2000). dl922-947 has also an impressive in vitro activity in ovarian carcinoma 
and was able to produce some long-term survivors in an aggressive xenograft 
model (Lockley et al. 2006). 
 
 
c) Oncolytic adenoviruses in combination cancer therapies 
 
   The safety and antitumour efficacy of dl1520 alone have been tested in 
numerous phase I and II clinical trials (Kirn 2001). In all cases safety was 
demonstrated, with the most common associated toxicity being flulike 
symptoms. Some of the most encouraging data were obtained from a phase II 
study using intratumoural administration of dl1520 in patients with advanced 
head and neck squamous cell carcinoma (Nemunaitis et al. 2000, 2001b). In all 
this trials adenovirus was administered alone and this mono-therapy has 
demonstrated limitations in efficacy. The best chance for complete tumour 
eradication lies in a multimodal cancer therapy approach utilizing oncolytic 
viruses in conjunction with chemotherapy and radiotherapy. The rationale for 
combination therapy was that  a greater antitumour effect was expected with 
combination treatment compared with single therapies; the therapies have 
different toxicity profiles and may result in enhanced efficacy without 
increased adverse events; no overlapping resistance between oncolytic viruses 
and chemotherapy and radiotherapy was anticipated; and it may be possible to 
lower treatment doses, thereby decreasing treatment cost, with combination 
therapy and still achieve a greater therapeutic efficacy than with single-
modality treatment. dl1520 has been used in conjunction with 
chemotherapeutic agents in clinical trials with evidence for potential 
synergistic antitumour activity. The use of dl1520 in conjunction with cisplatin 
(causes intrastrand DNA cross-links that block DNA replication), and 5-
fluorouracil (pyrimidine antagonist that inhibits DNA synthesis) has been 
examined in a phase II clinical trial involving head and neck carcinoma 
patients. dl1520 has been used in combination with leucovorin and 5-
fluorouracil in a phase II trial in patients with gastrointestinal carcinoma 
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metastatic to the liver and with gemcitabine in a phase I/II trial in patients with 
unresectable pancreatic carcinoma (Kruyt and Curiel 2002, Post et al. 2003). A 
variant of dl1520, H101, an E1B-55KDa-deleted adenovirus, was tested in a 
phase III study. In this trial the adenovirus was given by intratumoural 
injection to patients who received cisplatin-based chemotherapy. In studies of 
patients with squamous cell cancer of the head and neck or of the oesophagus, 
the response rate was significantly higher (78%) in patients who received the 
combination of viral therapy and chemotherapy than in patients who were 
treated with chemotherapy alone (39%) (Xia et al. 2004, Wakimoto et al. 
2004). 
All these studies have shown that combined treatment dl1520-chemotherapy 
increases the therapeutic effects. There have been several theories proposed for 
the augmented therapeutic effects of combined oncolytic adenoviruses and 
chemotherapy and the mainly one is that chemotherapy may enhance virus 
replication.  
Radiation has also been shown to be effective in combination with oncolytic 
virotherapy. Radiation therapy-induced tumour cell death is dependent on 
directly damaging DNA or indirectly through the formation of oxygen radicals 
that disrupt cellular pathways. This dual mechanism is different from how 
oncolytic viruses destroy tumour cells. This has led to several preclinical trials 
looking at the role of combining these two modalities. Intra-arterial injections 
of dl1520 in conjunction with total body irradiation (5 Gy) were evaluated in 
subcutaneous human malignant glioma xenograft models that were either p53 
mutant or p53 wild-type (Geoerger et al. 2003). Significant tumour growth 
delays were noted in the p53 mutant tumours receiving combination therapy 
versus monotherapies (30 days versus 10–15 days). The combination of low 
doses of dl1520 with a single 10 Gy dose of radiation significantly delayed the 
growth of xenograft tumours induced in athymic mice by the injection of 
anaplastic thyroid carcinoma cell lines (Portella et al. 2003).  Qian et al. (2005) 
have observed an increase of viral uptake in irradiated cells, and suggested a 
crucial role for a protein involved in adenovirus endocytosis, Dynamin 2. In 
summary, these preclinical studies in combining oncolytic adenoviruses with 
radiation therapy provided several important findings. Radiation did not appear 
to impair viral replication (Rogulski et al. 20001, Geoerger et al. 2003, Lamfers 
et al. 2002, Chen et al. 2001). There also appears to be no additive toxicities 
noted in the virus plus radiation-treated groups compared with the 
monotherapy groups (Rogulski et al. 2000, Chen et al. 2001). Furthermore, 
these preclinical studies point to enhanced antitumour effects when compared 
with monotherapy. Another interesting finding is, like in combination with 
chemotherapy, the order in which oncolytic adenoviral therapy and radiation 
therapy are administered may be important.  
dl1520 appears to be a good candidate also in combination with gene therapy 
and for this reason a new therapeutic strategy, called “targeting gene-
virotherapy”, is proposed. Basically, the antitumour gene is inserted into the 
tumour-specific replicative viral vector which then delivers the antitumour 
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gene to the tumour cells.  There are many ways to construct tumour-specific 
replicative viral vectors. It was constructed the modified adenoviral vector 
pZD55, with E1B55KDa deleted, but E1A remained, which specifically 
targeted p53-deficient tumour cells. The recombinant adenovirus was named 
ZD55, and it is similar to ONYX-015, but it is Ad5, not Ad2/Ad5 fusion virus, 
and furthermore there is a cloning site in ZD55 which is convenient to insert an 
exogenous gene into it (Zhang et al. 2003). Another way to construct tumour-
specific replicative viral vectors is to introduce a tumour-specific promoter to 
control the essential elements of viral replication, such as E1A and E1B. 
Therefore, these viruses and the inserted antitumour genes can only be 
replicated and expressed in tumour cells (Chiocca 2002). Many tissue-specific 
promoters are available for constructing tumour cell-specific replicative 
adenoviruses, such as AFP promoter for hepatic cancer, PSA promoter for 
prostate cancer, MUC-1 promoter for breast cancer and hTERT promoter.  
 
 
 
1.2 Angiogenesis is a novel therapeutic target for cancer treatment 
 
   One of the major obstacle to the successful application of therapeutic 
strategies based on replicating oncolytic viruses is represented by the poor 
distribution of viral particles throughout the tumour mass. This insufficient 
distribution is due to many causes among which there are physical barriers. In 
fact viruses delivered via the vasculature must cross the blood vessel 
endothelium and any layer of matrix that separate the endothelial cells from the 
tumour represent an obstacle for viral dissemination. Also host-derived 
connective tissue, including components of the basement membrane and the 
extracellular matrix (ECM), acts as a passive barrier to viral spread.  In 
addition to the physical barriers solid tumours contain physiologically different 
sub-compartments which may influence virus entry, diffusion and half-life. For 
example, in areas of necrosis or calcification, common to growing tumour 
masses in vivo, the prevailing microenvironment is characterized by hypoxia, 
acidosis and enhanced proteolytic activity, which may affect the virus particle 
itself or modify the cell surface of nearby live tumour cells in an unfavorable 
manner (Cairns et al. 2006).  
Moreover, tumour vessels are structurally and functionally abnormal. In 
contrast to normal vessels, tumour vasculature is highly disorganized, vessels 
are tortuous and dilated, with uneven diameter, excessive branching and shunts 
(Fig. 6). 
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Figure 6: Abnormal tumour vessels 
Tumour vessels are disorganized with shunts, occlusions, blind ends and breaks in vessel walls 
 
 
This may be due to an imbalance of angiogenic regulators, such as vascular 
endothelial growth factor (VEGF) and angiopoietins. Consequently, tumour 
blood flow is chaotic and variable (Baish and Jain 2000). In terms of their ultra 
structure, tumour vessels are also abnormal: their walls have numerous 
‘openings’ (endothelial fenestrae, vesicles and transcellular holes), widened 
interendothelial junctions, and a discontinuous or absent basement membrane. 
In addition, the endothelial cells are abnormal in shape, growing on top of each 
other and projecting into the lumen and, as a result of vascular 
hyperpermeability, tumour vessels are unable to maintain gradients between 
vascular and interstitial pressures, which contributes to interstitial 
hypertension. This lack of pressure gradient also impairs the flow of fluids, 
macromolecules and therapeutic agents. All these pathophysiological 
characteristics of solid tumours compromise the delivery and effectiveness of 
conventional cytotoxic therapies as well as molecular targeted therapies.  
Recently, a number of strategies to enhance the delivery of viruses into solid 
tumours have been proposed (McKee et al. 2006, Cairns et al. 2006, 
Minchinton and Tannock 2006). For example, given the physical barriers to 
oncolytic viruses, pre-treatment with proteolytic enzymes, e.g. hyalorunidase 
or collagenase, could alter the ECM and thus facilitate virus penetration. 
Therefore I have decided to evaluate the effects of a combined treatment 
between the oncolytic adenovirus dl922-947 and Bevacizumab, a recombinant 
humanized monoclonal antibody to the VEGF. 
Bevacizumab, has been tested in the clinic and has shown promising results 
(Ferrara et al. 2004, Gordon et al. 2001, Yang et al. 2003). Additionally, when 
combined with chemotherapy or radiotherapy, Bevacizumab has shown 
additive to synergistic effects on tumour inhibition (Ferrara et al. 2004, 
Hurwitz et al. 2004, Gerber and Ferrara 2005). A recent study on preclinical 
 19
model demonstrated that inhibition of carcinoma cell-derived VEGF by 
Bevacizumab reduced macrophage infiltration and activity, angiogenesis, 
vascular leakage, extracellular fluid volume in KAT-4 tumours (Salnikov et al. 
2006). Moreover Ad-mda7, a recombinant adenoviral vector of melanoma 
differentiation associated gene-7, with a potent antitumour and antiangiogenic 
activity both in vitro and in vivo, in combination with Bevacizumab treatment 
produces a synergistic and complete inhibitory effect on lung tumour 
xenografts.  
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2. AIMS OF THE STUDY 
 
 
   Thyroid carcinoma accounts for roughly 1% of all new malignant disease. Of 
these, at least 94% are differentiated thyroid carcinomas that derive from the 
follicular epithelial cells; and are either papillary thyroid carcinoma or 
follicular thyroid carcinoma. Another 5% are medullary thyroid carcinoma, a 
neuroendocrine tumour and the remaining 1% are anaplastic thyroid carcinoma 
that generally derive from dedifferentiation of the differentiated type. 
Anaplastic thyroid carcinoma is associated with a disease-specific mortality of 
almost 100% (Pierie et al. 2002, Xu et al. 2001, McIver et al. 2001, Haigh et al. 
2001, Passler et al. 1999, Hundahl et al. 1998). Patients with anaplastic 
carcinoma usually present with widespread local invasion and a high frequency 
of distant metastases (Sherman 1999). Treatment of anaplastic-type carcinoma 
is generally palliative in its intent for a disease that is rarely cured and almost 
always fatal. The median survival from diagnosis ranges from 3 to 7 months. 
Therefore, is important to find new therapeutic strategies and oncolytic viruses 
seem to be a good candidate. The first replication-competent adenoviral mutant 
described was dl1520 and in it was previously demonstrated that dl1520 is 
active against ATC cell lines and tumour xenografts, however high multiplicity 
of infections (MOIs) of dl1520 were used (Portella et al. 2002). This limited 
efficacy observed against ATC cells highlights a need for oncolytic 
adenoviruses with higher replication efficiency and killing activity. 
In this study I want to evaluate a therapeutic approach of anaplastic thyroid 
carcinoma based on the use of a second-generation adenoviral mutant, dl922-
947. This adenovirus lacks in Conserved Region 2 of E1A gene and is able to 
replicate in cells with an altered G1-S checkpoint. I want to demonstrate that 
dl922-947 has a higher efficiency to kill a range of human anaplastic thyroid 
cell lines respect to dl1520. One of the major obstacle to the successful 
application of therapeutic strategies based on replicating oncolytic viruses is 
represented by the poor distribution of viral particles throughout the tumour 
mass. This is the consequence of a compromised vascular supply with necrotic 
areas, a distorted functional properties of tumour vessels and a elevated tumour 
interstitial fluid pressure. In order to improve the delivery of the virus into the  
tumour, I want to apply a strategy based on the use of Bevacizumab a 
monoclonal antibody against VEGF. I want to demonstrate that administration 
of Bevacizumab increases the uptake of dl922-947 and that the combined 
treatment Bevacizumab/dl922-947 significantly improves the effects dl922-947 
against ATC tumour xenografts.  
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3. MATERIALS AND METHODS 
 
 
3.1 Cell lines 
   The human anaplastic thyroid carcinoma cell lines used in the study are 
ARO, FRO, KAT-4, Cal 62 and BHT-101. ARO and FRO human thyroid 
anaplastic carcinoma cell lines were obtained by Dr. Juillard (University of 
California LA). KAT-4 cell line was established by dr. Ain (University of 
Kentucky, Lexington, KY). Cal 62 cell line was obtained from Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig, 
Germany), German Collection of Microorganisms and Cell Cultures. BHT-101 
cell line was established by Dr. Palyi, (National Institute of Oncology, 
Hungary). The NPA line derives from poorly differentiated papillary 
carcinoma and was obtained by Dr. G. J. Juillard. The FB1 cell line derives 
from a follicular carcinoma. Human embryonic kidney HEK-293 cells were 
obtained from American Type Culture Collection (Manassas, VA). 
Cells were grown in DMEM medium supplemented with 10% FCS and 
ampicillin/streptomycin. 
 
 
3.2 Preparation of adenoviruses 
   dl1520 (ONYX-015) is a chimaeric human group C adenovirus (Ad2 and 
Ad5) that has a deletion between nucleotides 2496 and 3323 in the E1B region 
that encodes the 55- kDa protein. In addition, there is a C to T transition at 
position 2022 in region E1B that generates a stop codon at the third codon of 
the protein. 
dl922-947 is a second generation adenoviral mutant that has a 24-bp deletion in 
E1A Conserved Region 2 (CR2) therefore, is unable to induce progression 
from G1 into S-phase of quiescent cells. 
AdGFP is a non replicating E1 and E2-deleted adenovirus encoding green 
fluorescent protein.  
Ad5wt is a non-mutant adenovirus used as control adenovirus. 
Viral stocks were expanded and titered in the human embryonic kidney cell 
line HEK-293, which expresses the E1 region. Stocks were stored at -80°C 
after the addition of glycerol to a concentration of 50% vol/vol. Virus titer was 
determined by plaque-forming units (pfu) on the HEK-293 cells.  
 
 
3.3 Viability assay 
   For the evaluation of the cytotoxic effects of the dl922-947 virus, cells were 
seeded in 96-well plates, and 24 h later increasing concentrations of dl922-947, 
dl1520 or control adenovirus Ad5wt were added to the incubation medium. For 
the evaluation of the cytotoxic effects of the dl922-947 virus in combination 
with paclitaxel, cells were seeded in 96-well plates, and 24 h later were treated 
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with increasing concentrations of paclitaxel. After 24 h increasing 
concentrations of dl922-947 was added to the incubation medium.  
Ten-twelve days later, the media were fixed with 10% TCA and stained with 
0.4% sulforhodamine B in 1% acetic acid. The bound dye was solubilized in 
100 µl of 10 mM unbuffered Tris HCl solution and the optical density was 
determined at 540 nm in a microplate reader (Biorad). The percent of survival 
rates of cells exposed to adenovirus vectors were calculated by assuming the 
survival rate of untreated cells to be 100%. 
 
 
3.4 Quantitative PCR of adenoviruses and analysis of adenoviral genes 
expression 
   To quantify the amount of viral genomes, cells were infected with dl922-947, 
dl1520, and Ad5wt at concentration of 0,1 pfu, 1 pfu and 100 pfu.  After 48 h 
of infection, cell media was collected and viral DNA extracted using a 
QIAamp DNA mini kit (Valencia, CA, USA) and then quantified by Real-time 
PCR using assay-specific primer and probe. Real time-based assay was 
developed using the following primers: 5'-GCC ACC GAG ACG TAC TTC 
AGC CTG -3' (Upstream primer) and 5'- TTG TAC GAG TAC GCG GTA 
TCC T- 3' (Downstream primer) for the amplification of 143 bp sequence of 
the viral hexon gene (from bp 99 to 242 bp). For quantification, a standard 
curve was constructed by assaying serial dilutions of dl1520, dl922-947 and 
Ad5wt viruses ranging from 0,1 pfu to 100 pfu.  
To analyze the expression of adenoviral genes ARO and KAT- 4 cells were 
infected with 10 pfu of dl922-947, dl1520 and Ad5wt, and harvested at 24 
hours post infection.  Cells were dissolved in 1 ml Trizol (Invitrogen) and RNA 
extraction was performed. RNA quality was evaluated by agarose gel 
electrophoresis, DNAse treatment was performed. 1 μg of total RNA was 
reverse transcribed using the a SuperScriptTM II Reverse Transcriptase Kit 
(Invitrogen) and the expression of E1A 13 S and Penton adenoviral genes 
monitored using Real-time PCR with the following specific primers, E1A 13 S 
Forward: 5’- AAT GGC CGC CAG TCT TTT- 3’ and Reverse: 5’ - ACA CAG 
GAC TGT AGA CAA -3’. Penton Forward: 5’ – TAA CCA GTC ACA GTC 
GCA AG – 3’ and Reverse 5’ – CCC GCG CCT TAA ACT TAT T – 3’. As 
control the expression of β-actin gene was monitored using the following 
primers: Reverse: 5’ – TCG TGC GTG ACA TTA AGG AG – 3’ and Forward: 
5’ – GTC AGG CAG CTC GTA GCT CT – 3’. To calculate the relative 
expression levels it was used the 2–[delta][delta]Ct method.  Negative controls, 
samples without RT PCR or cDNA template were included in every PCR run, 
always resulting negative (data not shown). 
 
 
3.5 AdGFP infection 
   Cells were detached, counted, and plated in 6 well plate at 70% cell density. 
After 24 h cells were treated with Bevacizumab and then, after 48 h of 
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incubation, infected with AdGFP, a non replicating E1 and E2-deleted 
adenovirus encoding green fluorescent protein, at different multiplicity of 
infectio (MOIs). After 24 h of infection cells were trypsinised, washed, and 
resuspended in 300μl of PBS and analyzed for GFP expression on a 
fluorescence-activated cell sorter (FACS) cytometer (Dako Cytomation, 
Carpinteria, CA) and Summit version 4.3 software (Dako, Carpinteria, CA). 
For the evaluation of Bevacizumab effects on adenoviral entry and GFP 
expression, KAT-4 cells were treated for 24 h with Bevacizumab and then 
infected for 48 h with AdGFP. Cells were harvested and prepared for FACS 
analysis as previously described. 
 
 
3.6 Tumorigenicity assay and analysis of viral genome 
   All experiments were performed in six-week-old male athymic mice 
(Charles-River, Italy).  
In the experiment performed to evaluated the effects of dl922-947 and  dl1520 
on ATC xenografts, 60 athymic mice were inoculated subcutaneously with 1 x 
106 ARO or KAT-4 cells and 20 days later, when tumours were clearly 
detectable the animals were divided into three groups (20 animals/group) and 
tumour size was evaluated. Two groups received intratumorally respectively 1 
x 108 pfu of dl922-947 and dl1520 two times per week and one group was used 
as control group.  
To evaluate the effects of dl922-947 in combination with  Bevacizumab KAT-
4 cells (1x106) were injected into the right flank of 80 athymic mice. After 40 
days, when tumours were clearly detectable, the animals were divided into four 
groups (20 animals/group), and tumour volume was evaluated. Two groups 
received Bevacizumab (5 mg/Kg/mouse) intraperitoneally (i.p.) the day 0 and 
6, and the day 2 and 4 dl922-947 (2,5 x 106 pfu) was injected in the 
peritumoural area in a group treated with Bevacizumab and in an untreated 
group. This treatment was repeated for 4 week.  
Tumour diameters were measured with calipers every day until the animals 
were killed. Tumour volumes (V) were calculated by the formula of rotational 
ellipsoid: V= A x B2/2 (A= axial diameter, B= rotational diameter). No mouse 
showed signs of wasting or other visible indications of toxicity. All mice were 
maintained at the Dipartimento di Biologia e Patologia Animal Facility. 
Animal experimentations described here have been conducted in accordance 
with accepted standards of animal care and in accordance with the Italian 
regulations for the welfare of animals used in studies of experimental 
neoplasia, and the study was approved by our institutional committee on 
animal care.  
To evaluate the genome equivalent copies of dl922-947 and dl1520 in tumour 
xenografts, 3 animals bearing ARO or KAT-4 tumour xenografts were injected 
in the peritumoral area with dl1520 or dl922-947 (1 x 108 pfu).  After 48 hours 
treated and control animals were sacrificed, tumours excised, viral DNA 
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extracted using a QIAamp DNA mini kit (Valencia, CA, USA) and viral 
replication evaluated by Real-time PCR using adeno hexon primers.  
To evaluate the genome equivalent copies of dl922-947 in animals treated with 
Bevacizumab and dl922-947, KAT-4 cells (1x106) were injected into the right 
flank of 10 athymic mice. After 20 days, when tumours were clearly detectable 
animals were divided in two groups. A group received Bevacizumab (5 
mg/kg/mouse) i.p. two times, at day 0 at day 5, and at day 6 dl922-947 (1 x108 
pfu) was injected in the peritumoural area. After 48 hours animals of both 
groups were sacrificed, tumours excised, viral DNA extracted using a QIAamp 
DNA mini kit (Valencia, CA, USA) and viral replication evaluated by Real 
Time PCR using adeno hexon primers.  
 
 
3.7 Tissue preparation and confocal microscopy 
   KAT-4 cells (1x106 cells) were injected into the right flank of 20 athymic 
mice, and after 20 days, when tumours were clearly detectable, animals were 
randomised into two groups (10 animals/group). Bevacizumab (5 
mg/kg/mouse) was administered  i.p. only in one group and after 5 days both 
groups received the administration of AdGFP (1 x 108 pfu) within the tumour. 
At the end of experiment the animals were sacrificed and the tumour were 
excised, snap frozen in liquid nitrogen and cut with a cryostat in thick sections 
for microscopic investigation. Sections were mounted onto untreated slides and 
coverslipped in Slow fadeTM antifade (Molecular Probes) for microscopic 
investigation. Ten sections were sampled across the entire tumour mass to 
ensure they were representative of the distribution of GFP positive signal into 
the tumour mass. For each slice ten images at high resolution were sampled 
from the periphery to the core of the section. 
Images were acquired using a Zeiss LSM 510 Meta argon/krypton laser 
scanning confocal microscope, with fluorescence excitation lines 488 nm and 
emission filter BP505-550, a x20 and x63 oil immersion (PlanApochromat, NA 
= 1.4, Zeiss) objectives, pixel depth 12 bit, , fixed box sizes of 512 x 512 
pixels, pinhole below 1 Airy unit. Four images from each optical section were 
averaged to improve the signal to noise ratio. The colour scheme used was 
green for GFP-labeled structures. 
 
 
3.8 Detection of cell surface coxsackie-adenovirus receptor (CAR) 
   The methods is described in detail in the publication at the end of the 
references.  
 
 
3.9 Human thyroid tissue samples and Real Time RT-PCR 
   The methods is described in detail in the publication at the end of the 
references.  
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3.10 Protein extraction and Western blot analysis 
   The methods is described in detail in the publication at the end of the 
references. 
 
 
3.11 Statistical analysis 
   Comparisons among different treatment groups in the experiments in vivo 
were made by the ANOVA method and the Bonferroni post hoc test using a 
commercial software (GraphPad Prism 4). Assessment of differences among 
rate of tumour growth in mice was made for each time point of the observation 
period. The analysis of the cell killing effect in vitro was also made by 
ANOVA method and the Bonferroni post hoc test. For all the other 
experiments comparisons among groups were made by ANOVA method and t 
test. 
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4. RESULTS AND DISCUSSION 
 
 
   The efficacy of oncolytic adenoviruses as therapeutic agents relies on the 
capability of target neoplastic cells to bind, internalize, and sustain the 
replication of adenoviruses. I analyzed the infectivity of a panel of human 
thyroid carcinoma cell lines with a GFP transducing adenovirus (AdGFP), 
using increasing concentration from 1 pfu to 100 pfu. The results are shown in 
Fig. 7  
 
 
 
Figure 7: Adenoviral infectivity in human thyroid carcinoma cell lines 
ATC cell lines ARO and KAT-4 are the less sensitive to AdGFP infection at all MOIs used, 
whereas FRO and Cal62 cells display a higher percentage of GFP-expressing cells. Follicular 
thyroid carcinoma cell line FB1 and papillary thyroid carcinoma cell line NPA show about 
90% of GFP-positive cells at 10 MOI. HEK-293 cells were used as a positive control 
 
 
The anaplastic thyroid carcinoma cell lines ARO, FRO, and KAT-4 display the 
lowest percentage of fluorescent cells at all the multiplicity of infection (MOIs) 
used; indeed 100 pfu/cell are required to obtain greater than 50% ARO and 
KAT-4 positive cells, whereas at 10 pfu/cell, about 50% of FRO cells are 
positive. Conversely, follicular thyroid carcinoma cell line FB1 and papillary 
thyroid carcinoma cell line NPA showed about 90% of GFP positive cells at 10 
MOIs. As a positive control HEK-293 cells were used.  
   Because adenoviral infection occurs via the attachment to the CAR (Coyne et 
al. 2005), we analyzed CAR expression by Western blot; two CAR-specific 
bands of 44 and 46 kDa, respectively, were detected in all the samples (Fig. 8).  
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Figure 8: CAR expression in human thyroid carcinoma cell lines 
Cal 62, FRO, and ARO cells show low expression of total CAR levels, whereas FB1, KAT-4, 
and NPA cells express the higher of total CAR levels. Equal amounts of protein lysates (50 μg) 
were loaded.  
 
 
However, certain differences were observed in their levels; in ATC cell lines, 
variable levels ranging from very low to intermediate were observed; the 
papillary thyroid carcinoma-derived NPA cell line, the follicular carcinoma-
derived FB-1 cell lines, and the ATC-derived KAT-4 cell line express the 
highest CAR levels.  
   A cytofluorimetric analysis was performed to evaluate the presence of CAR 
on the cell membrane (Fig. 9). 
 
 
 
Figure 9: Cytofluorimetric analysis of CAR expression on the membrane of thyroid 
carcinoma cell lines 
Flow cytometry analysis shows the absence of cell surface CAR expression in FRO, NPA, Cal 
62, and FB1 thyroid cancer cell lines. ARO and KAT-4 cell lines show the presence of CAR on 
the membrane. HEK-293 cells were used as positive control.  
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The result shows the absence of CAR on the cell surface in FRO, NPA, Cal 62, 
and FB1 cells. This observation suggests a CAR-independent entry of AdGFP 
in these cell lines. The cell lines ARO and KAT-4 show the presence of CAR 
on the cell membrane despite being the less susceptible to adenoviral infection.  
   To confirm that anaplastic thyroid carcinomas express low levels of CAR, we 
evaluated the CAR mRNA levels in human thyroid carcinoma tissues by RT-
PCR. Significantly lower levels (**P<0.01) in CAR gene expression were 
observed in papillary carcinomas, follicular carcinomas, and anaplastic thyroid 
carcinomas with respect to normal thyroid samples (Fig. 10).  
 
 
 
Figure 10: CAR expression in thyroid carcinoma tissues 
Three normal thyroid samples (1–3), eight anaplastic (4–11), two follicular (12 and 13), and 
four papillary (14–17) thyroid carcinomas were used for Real-ime RT-PCR analysis of CAR 
expression, showing a reduction in CAR mRNA levels in all neoplastic tissues with respect to 
normal thyroid samples. 
 
 
ATC cell lines display a low susceptibility to adenoviral infection and this was 
also demonstrated by our study with dl1520 of which high MOIs were used in 
all experiments (Portella et al. 2002 and 2003, Libertini et al. 2007). Therefore 
it is necessary to find a new oncolytic adenovirus with higher antineoplastic 
activity. 
   To this aim I have evaluated the effects of a second-generation adenoviral 
mutant, dl922-947, in the treatment of anaplastic thyroid carcinoma. 
In order to show that dl922-947 has a higher efficiency to kill human anaplastic 
thyroid cell lines with respect to dl1520, I compared the effects of both 
adenoviruses on ARO, FRO, KAT-4 and also on another anaplastic carcinoma 
cell line, BHT-101 cells. Ad5wt virus was used as a control. Cells, seeded in 
96-well plates, were infected with increasing concentrations of dl922-947, 
dl1520 or Ad5wt. Fig. 11 reports graphics about every cell line used in 
experiment. In the diagrams the percentage of cell survival is represented as a 
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function of used pfu/cell. In ARO, KAT-4 and BTH-101 cells dl922-947 has a 
higher cytopathic effects with respect to dl1520. In particular, in ARO e KAT-
4 cells dl922-947 induces a percentage of mortality of about 90% at 
concentration of 0,0001 pfu/cell. In FRO cells the effects of the three 
adenoviruses are similar.  
This first result indicates that dl922-947 has a higher killing efficiency against 
human anaplastic thyroid cell lines. 
 
 
 
Figure 11: Cytopathic effects of dl922-947, dl1520 and Ad5wt on human anaplastic 
thyroid  carcinoma cell lines 
ARO, KAT-4, FRO and BHT-101 cells were infected with increasing concentration of dl922-
947, dl1520 and Ad5wt. In ARO, KAT-4 and BTH-101 cells dl922-947 has a higher cytopathic 
effects with respect to dl1520 while in FRO cells the effects of the three adenoviruses are 
similar. 
 
 
   Replication of viruses into cells is a specific characteristic of their life-cycle. 
In order to establish if the higher degrees of cytopathic effects observed 
infecting ATC cells with dl922-947 are due to the more efficient viral 
replication within ATC cells, I have evaluated the efficiency of replication of 
dl922-947, dl1520 and Ad5wt on ARO, KAT-4, FRO and BHT-101 cells. 
These cells were infected respectively with a MOIs of 0,1 pfu, 1 pfu, and 100 
pfu of dl922-947, dl1520 and Ad5wt. After 48 h of infection the amount of 
viruses genome was quantified  by Real-Time PCR using specific primers for 
the amplification of 143 bp sequence of the viral hexon gene. Fig. 12 shows 
graphics relative to every cell line used in experiment. The amount of viral 
DNA, expressed in log scale, is reported on y-axis.  The viral genome copies 
analysis shows higher levels of dl922-947 replication with respect to dl1520 in 
ARO cells, at MOIs of 1 pfu and 100 pfu (**p<0,01). In KAT-4 cells a 
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significant difference (*p<0,05), between the replication of dl922-947 and 
dl1520, is present only at MOI of 0,1 pfu unlike BHT-101 cells which have a 
significant difference (*p<0,05) at MOI of 1 pfu. In FRO cells, in which dl922-
947 and dl1520 induce the same cytopathic effects, dl922-947 has a higher 
efficiency of replication with respect to dl1520 at MOIs of 1 pfu and 100 pfu 
(**p<0,01). Since in FRO cells no significant differences were observed in cell 
killing, it is possible that other mechanisms, besides viral replication, are 
involved. 
These results demonstrate that dl922-947 has a higher replication and killing 
efficiency with respect to dl1520 in ATC cell lines, confirming its greater 
potentiality with respect to dl1520.  
 
 
 
 
Figure 12: Adenoviruses replication on ATC cell lines 
Viral DNA copies of ARO, KAT-4, FRO and BHT-101 cells infected respectively with a MOI 
of 0,1 pfu, 1 pfu, and 100 pfu of dl922-947, dl1520 and Ad5wt. dl922-947 has a higher 
replication efficiency with respect to dl1520 in all ATC cell lines (*p<0,05; **p<0,001). 
It is important to note that in all cell lines the differences of the amount of viral DNA copies 
between dl922-947 and Ad5wt are significant (p<0,05; p<0,001) 
 
 
   In order to analyze the viral life-cycle in infected ATC cells I selected two 
adenoviral genes, E1A 13 S and Penton, whose expression is correlated 
respectively with early and  late stage of the adenoviral life-cycle. I have 
analyzed the expression of these genes in ARO and KAT-4 cells infected 
respectively with MOIs of 10 pfu of dl1520, dl922-947 and Ad5wt. After 24 h 
of infection, the expression levels of E1A 13 S and Penton were measured by 
Real Time RT PCR using the forward and the reverse primers for each gene. 
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Expression levels of E1A 13 S and Penton are reported in Fig. 13. Genes 
expression levels are expressed in arbitrary units with respect to the β-actin 
gene used as control gene.  
 
 
 
 
 
Figure 13: E1A 13 S and Penton expression levels on ARO and KAT-4 cells 
A) In ARO cells the infection with dl922-947 induces an E1A 13 S expression ten fold greater 
with respect to dl1520 and Ad5wt; in KAT-4 cells expression levels of E1A 13 S are five fold 
greater after dl922-947 infection with respect to dl1520 and Ad5wt. Expression levels of E1A 
13 S are expressed in arbitrary units respect to the β-actin gene used as control gene. 
B) In ARO cells the infection with Ad5wt induces a late gene expression four fold higher with 
respect to dl922-947 and dl1520; in KAT-4 cells Ad5wt induces a Penton expression ten fold 
greater with respect to the other adenoviruses. Expression levels of E1A 13 S are expressed in 
arbitrary units respect to the β-actin gene used as control gene. 
 
 
In ARO cells the infection with dl922-947 induces an E1A 13 S expression ten 
fold greater with respect to dl1520 and Ad5wt; in KAT-4 cells expression 
levels of E1A 13 S are five fold greater after dl922-947 infection with respect 
to dl1520 and Ad5wt (Fig. 13 A). In ARO cells the infection with Ad5wt 
induces a Penton gene expression four fold higher with respect to dl922-947 
and dl1520; in KAT-4 cells Ad5wt induces a Penton expression ten fold 
greater with respect to the other adenoviruses (Fig. 13 B). This results show a 
different early and late gene expression after infection with three adenoviruses; 
E1A 13 S gene is highly expressed after dl922-947 infection, while Penton 
gene is more expressed after Ad5wt infection. This discrepancy could be 
explain considering that Ad5wt is a non-mutant adenovirus. In fact in wt 
adenovirus the expression of early genes is switched off at the beginning of late 
gene expression (Berk 1986). 
   To evaluate whether dl922-947 inhibited the growth of ARO and KAT-4 
tumour xenografts 60 athymic mice were inoculated subcutaneously ARO cells 
or KAT-4 cells. Twenty days later, when tumours were clearly detectable, 
KAT-4
0
0,2
0,4
0,6
0,8
1
1,2
dl922-947 dl1520 Ad5w t
E1
A
 1
3 
S 
ex
pr
es
si
on
 
(a
rb
itr
ar
y 
un
its
)
ARO
0
0,2
0,4
0,6
0,8
1
1,2
dl922-947 dl1520 Ad5w t
E1
A
 1
3 
S 
ex
pr
es
si
on
 
(a
rb
itr
ar
y 
un
its
)
ARO
0
1
2
3
4
5
dl922-947 dl1520 Ad5w t 
Pe
nt
on
 e
xp
re
ss
io
n 
(a
rb
itr
ar
y 
un
its
)
KAT-4
0
2
4
6
8
10
12
dl922-947 dl1520 Ad5w t 
Pe
nt
on
 e
xp
re
ss
io
n 
(a
rb
itr
ar
y 
un
its
)
A B 
 32
animals were divided in three groups. Two groups received intratumourally 
respectively 1 x 108 pfu of dl922-947 and dl1520 two times per week and one 
group was used as control group. Tumour diameters were measured with 
calipers every day until the animals were killed.  In Fig. 14 effects of dl922-
947 and dl1520 on ARO and KAT-4 tumours xenografts are represented.  
 
 
 
Figure 14: Inhibition of tumour growth on ARO and KAT-4 tumour xenografts 
Relative tumour growth of animals treated with dl922-947, dl1520 and control groups. Starting 
from day 10, a significant decrease (p<0.01) in tumour volume was observed in dl922-947 
treated animals with respect to the animals untreated or treated with dl1520 
 
 
Tumour volume, expressed in percentage of control tumours volume, is 
reported as a function of days of treatment. Starting from day 10, a significant 
decrease (p<0.01) in tumour volume was observed in dl922-947 treated 
animals with respect to the animals untreated or treated with dl1520. The 
difference in tumour growth was maintained until the end of the experiment. 
Unfortunately, control animal were sacrificed being the tumours too large and 
the evaluation of the survival curve was not possible. None of the treated 
animals suffered from any clinically apparent side effects attributable to viral 
administration. Moreover it is important to note that in 10% of the animals 
treated with dl922-947 a complete eradication of the tumour was obtained (data 
non shown).  
   Next I have evaluate the replication of dl922-947 into the tumours. Three 
animals bearing ARO or KAT-4 tumour xenografts were injected in the 
peritumoural area with dl1520 or dl922-947 (1 x 108 pfu). After 48 hours 
treated and control animals were sacrificed, tumours excised, viral DNA 
extracted and viral replication evaluated by Real-time PCR using specific 
primers for the amplification of 143 bp sequence of the viral hexon gene. In 
Fig. 15 the amount of viral DNA copies from ARO and KAT-4 tumours, is 
represented. 
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Figure 15: Adenoviruses replication in ARO and KAT-4 tumour xenografts 
Genome equivalent copies of animals treated with dl922-947 and dl1520 groups. In both ARO 
and KAT-4 tumours dl922-947 has a higher efficiency of replication with respect to  dl1520. 
 
 
In both ARO and KAT-4 tumours dl922-947 has a higher efficiency of 
replication with respect to  dl1520. This result indicates that the inhibition of 
tumour growth and efficiency of viral replication are events strictly correlated.  
The results obtained in vitro and in vivo confirm that dl922-947 has a higher 
killing efficiency with respect to dl1520 and encourage to use dl922-947 in 
ATC treatment. 
   It is unlikely that dl922-947 could be used as monotherapy, therefore, to 
enhance its therapeutic potential, I have proposed a therapeutic strategy based 
on combination dl922-947 plus paclitaxel, a mitotic inhibitor used in cancer 
chemotherapy. It is well know that paclitaxel is able to induce a G2/M arrest in 
cell cycle, moreover it has been reported that paclitaxel potentiates adenoviral 
oncolysis in non-small-cell lung cancer cells (AbouEl Hassan MA et al. 2006) 
and it is able to cause death in anaplastic thyroid cell lines (Pushkarev VM et 
al. 2004). Furthermore paclitaxel enhances the effects of the oncolytic 
adenovirus dl1520 against ATC cells (Portella et al. 2003). 
   ARO and KAT-4 cells were exposed to increasing concentrations of 
paclitaxel from 0,075 ng/ml to 2 ng/ml, alone or in combination with 
increasing concentrations of dl922-947 from 0,05 pfu/cell to 2,5 pfu/cell. Fig 
16 reports the percentage of cell survival as a function of paclitaxel 
concentration in ARO and KAT-4 cells. A significant increase in cell killing 
was achieved by paclitaxel/dl922-947 combination and the data are reported in 
the table below (table 2). This results indicate that the combination 
paclitaxel/dl922-947 has a higher killing efficiency with respect to the virus 
alone and this could represent a good tool for the treatment of ATC with 
respect to a monotherapy approach. 
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Figure 16: Effects of paclitaxel/virus combination 
In ARO and KAT-4 cell the combined treatment induces a significant increase in cell killing 
(percentages of cell killing are reported in table 2). 
 
 
Table 2: % mortality in ARO and KAT-4 cells after treatment paclitaxel plus dl922-947 
 
ARO cells Paclitaxel  
0 ng/ml 
Paclitaxel  
0,075 ng/ml 
Paclitaxel  
0,1 ng/ml 
dl922-947  
0 pfu 
0% 6% 15% 
dl922-947  
0,5 pfu 
38% 46% 62% 
dl922-947  
1 pfu 
57% 66% 71% 
 
KAT-4 cells Paclitaxel  
0 ng/ml 
Paclitaxel 
0,1 ng/ml 
Paclitaxel  
1 ng/ml 
Paclitaxel  
2 ng/ml 
dl922-947  
0 pfu 
0% 6% 34% 53% 
dl922-947 
0,05 pfu 
3% 14% 41% /////////// 
dl922-947  
0,5 pfu 
15% 35% //////////// 79% 
 
The percentages of cell killing are expressed for the virus alone, for the paclitaxel alone and for 
the combination virus/paclitaxel. In blue the percentages in which is present an additive effect 
are indicated. 
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   The successful application of therapeutic strategies based on replicating 
oncolytic viruses is limited by several obstacles and the major one is the 
incomplete viral dissemination within tumour mass. Compromised vascular 
supply and distorted functional properties of tumour vessels along with 
pathologically elevated tumour interstitial fluid pressure (PIF) are major factors 
limiting drug uptake in malignant tumours (Jain 1990 and 1999, Pietras et al. 
2001, Salnikov et al. 2003). Recently, a number of strategies to enhance the 
delivery of drugs into solid tumours have been proposed (McKee et al. 2006, 
Cairns et al. 2006, Minchinton and Tannock 2006). It has been suggested that 
vascular remodelling or normalization of tumour vessels induced by anti-
angiogenic treatment could improve the delivery of viruses to tumour cells. A 
series of studies have been performed using anti-angiogenic therapies in ATC 
treatment (Prichard et al. 2007) and in particular, a study conducted on KAT-4 
tumour xenografts suggests that Bevacizumab, a monoclonal antibody to 
VEGF, is able to reduce tumour PIF (Salnikov et al. 2006).  
   I have proposed an approach based on combination Bevacizumab/dl922-947 
in vivo. I have inoculated  KAT-4 cells (1 x 106 cells) into the right flank of 80 
athymic mice and after 40 days, when tumours were clearly detectable, animals 
were randomized into four groups. In two groups Bevacizumab (5 
mg/kg/mouse) was administered i.p. the day 0 and 6, and the day 2 and 4 
dl922-947 (2,5 x 106 pfu) was injected in the peritumoural area in a group 
treated with Bevacizumab and in an untreated group. This treatment was 
repeated for 4 week. Tumour diameters were measured with calipers every day 
until the animals were killed. In Fig. 17 tumour volume, expressed in 
percentage of volume of control tumours, is expressed as a function of days of 
treatment. It is important to note that since dl922-947 alone is able to reduce 
the growth of tumours in animals bearing ATC cells, a lower concentration of 
dl922-947 was used in this experiment with respect to the ones used in 
experiment shown in Fig. 14, in order to better evaluate the difference between 
the virus alone, and the virus in combination with Bevacizumab. The result 
shows that the combined treatment, Bevacizumab plus dl922-947, has a higher 
efficiency to reduce tumour growth with respect to the virus alone. 
The pre-treatment with Bevacizumab, probably decreasing the interstitial 
pressure or normalizing tumour vessels, improves the delivery and the 
distribution of the virus into tumour mass and enhances the effect on the 
inhibition of tumour growth. 
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Figure 17: Effects of dl922-947 plus Bevacizumab in KAT-4 tumours 
Relative tumour growth of animals treated dl922-947, Bevacizumab, dl922-947 plus 
Bevacizumab and control groups. The combined treatment, Bevacizumab plus dl922-947, is 
able to reduce tumour growth with a higher efficiency with respect to the virus alone. 
 
 
   In order to evaluate viral distribution in tumour tissues, KAT-4 cells were 
injected into the right flank of 20 athymic mice, and after 20 days, when 
tumours were clearly detectable, animals were randomised into two groups. 
Bevacizumab (5 mg/kg/mouse) was administered  i.p. only in one group and 
after 5 days both groups received the administration of AdGFP (1 x 108 pfu) 
within the tumour. At the end of experiment the animals were sacrificed and 
the tumour were excised, snap frozen in liquid nitrogen and cut with a cryostat 
in thick sections for microscopic investigation. Fig. 18 A reports images of 
confocal microscopy at different magnification; on the left the distribution of 
AdGFP alone is represented, on the right there is the AdGFP distribution after 
the pre-treatment with Bevacizumab.  
    Fluorescence is more diffuse and intense in animal tissues treated with 
AdGFP plus Bevacizumab with respect to the tissues treated with the virus 
alone. In Fig. 18 B a quantitative measure of fluorescence, expressed in 
arbitrary units, in both treatments is shown. The combined treatment 
AdGFP/Bevacizumab induces a fluorescence intensity six fold higher with 
respect to the virus alone (p<0,01). This result suggests that the pre-treatment 
with Bevacizumab is probably able to normalize tumour vessels so that it is 
possible to obtain a better dissemination of the virus into the tumour mass with 
respect to the absence of treatment. 
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Figure 18: Effects of Bevacizumab/AdGFP combination 
A) Intensity of GFP staining in tumour tissues treated with AdGFP and AdGFP plus 
Bevacizumab. The fluorescence is more diffuse and intense in animal tissues treated with 
AdGFP plus Bevacizumab with respect to the tissues treated with the virus alone. The images 
are at two different magnification, 10X and 60X. 
B) This diagram reports a quantitative measure of fluorescence, expressed in arbitrary units. 
The combined treatment AdGFP/Bevacizumab induces a fluorescence intensity six fold higher 
with respect to the virus alone. 
 
   Next I have decide to  evaluate the genome equivalent copies of dl922-947 in 
animals treated with Bevacizumab and dl922-947. KAT-4 cells were injected 
into the right flank of 10 athymic mice. After 20 days, when tumours were 
clearly detectable animals were divided in two groups. A group received 
Bevacizumab (5 mg/kg/mouse) i.p. two times, at day 0 at day 5, and at day 6 
dl922-947 (1 x108 pfu) was injected in the peritumoural area. After 48 hours 
animals of both groups were sacrificed, tumours excised, viral DNA extracted 
and viral replication evaluated by Real Time PCR using the forward and the 
reverse primers for  viral hexon gene. Fig. 19 reports the amount of viral DNA 
copies in the group treated with dl922-947 alone and in the group treated with 
dl922-947 plus Bevacizumab. The combined treatment dl922-
947/Bevacizumab induces a viral replication six fold higher (p<0,01) with 
respect to the virus alone. All these results demonstrated that the pre-treatment 
with Bevacizumab is able to improve the therapeutic effect of dl922-947 
adenovirus against ATC.  
 
 
AdGF Bevacizumab + AdGFP 
10 10
60 60
0
5
10
15
20
25
30
35
AdGFP Bevacizumab + AdGFP 
Fl
uo
re
sc
en
ce
 (a
rb
itr
ar
y 
un
its
)
X 
X X 
X 
A B 
 38
0
10000
20000
30000
40000
dl922/947 dl922/947/Bevacizumab
Vi
ra
l D
N
A 
co
pi
es
 
 
Figure 19: Effects of Bevacizumab/virus combination 
Genome equivalent copies of animals treated with dl922-947 and dl922-947 plus 
Bevacizumab. The combined treatment dl922-947/Bevacizumab induces a viral replication six 
fold higher with respect to the virus alone. 
 
 
   In order to evaluate if Bevacizumab is able to produce in vitro the same 
effects observed in vivo, I have performed a series of experiments on KAT-4 
cells. 
   In the first experiment I have evaluated the survival of KAT-4 cells treated 
for 48 h with Bevacizumab at concentrations of 0,1 μM and 0,25 μM and then 
infected with dl922-947 at MOIs of 0,01 pfu, 0,1 pfu and 1 pfu and. Fig. 20  
reports the percentage of cell survival as a function of used pfu/cell. No 
significant differences between the combined treatment Bevacizumab/dl922-
947 and the virus alone were observed. 
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Figure 20: Combined treatment dl922-947 plus Bevacizumab does not increase the 
mortality of KAT-4 cells in vitro 
KAT-4 cells were treated for 48 h with Bevacizumab at concentrations of 0,1 μM and 0,25 μM 
and then infected with dl922-947 at MOIs of 0,01 pfu, 0,1 pfu and 1 pfu and. No differences in 
the combined treatment with respect to the virus alone are observed. 
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   Then, I have evaluated the replication efficiency of combined treatment 
Bevacizumab/dl922-947 with respect to virus alone. I treated KAT-4 cells with 
Bevacizumab at concentrations of  0,25 μM, 0,5 μM and 1 μM and after 48 h I 
infected cells with dl922-947 at MOIs of 1 pfu and 10 pfu. After infection the 
amount of viruses genome was quantified  by Real-Time PCR using specific 
primers for the viral hexon gene. Fig. 21 reports the amount of viral DNA 
copies as a function of used pfu/cell. No significant differences between the 
replication of the virus alone and the virus in combination with Bevacizumab 
were observed. 
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Figure 21: Combined treatment dl922-947/Bevacizumab does not increase viral 
replication in KAT-4 cells in vitro 
KAT-4 cells were treated with Bevacizumab at concentrations of  0,25 μM, 0,5 μM and 1 μM 
and after 48 h were infected with dl922-947 at MOIs of 1 pfu and 10 pfu. After infection the 
amount of viruses genome was quantified  by Real-Time PCR. No differences in the combined 
treatment with respect to the virus alone are observed. 
 
 
   Finally, I have performed a FACS analysis in order to evaluate the infectivity 
of KAT-4 cells in presence of Bevacizumab. KAT-4 cells were pre-treated with 
two concentrations of Bevacizumab (0,5 μM and 1 μM) for 48 h and then 
infected with AdGFP at MOIs of 100 pfu, 200 pfu and 300 pfu. Fig. 22 reports 
the fluorescence emission, expressed in arbitrary units, as a function of used 
pfu/cell. FACS analysis showed that Bevacizumab treatment does not induce 
an increase in the infectivity of KAT-4 cells. 
The data obtained treating in vitro KAT-4 cells with Bevacizumab and dl922-
947, demonstrate  that the effects of inhibition of tumour xenografts growth are 
not due to a direct activity on ATC cells. It is possible that the effects observed 
treating ATC xenografts with Bevacizumab and dl922-947 are due to an 
activity against tumour stroma cells.  
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Figure 22: Combined treatment AdGFP/Bevacizumab does not increase the infectivity in 
KAT-4 cells 
KAT-4 cells were pre-treated with two concentrations of Bevacizumab (0,5 μM and 1 μM) for 
48 h and then infected with AdGFP at MOIs of 100 pfu, 200 pfu and 300 pfu. No differences, 
in the infectivity of KAT-4 cells, in the combined treatment with respect to the virus alone are 
observed. 
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5. CONCLUSIONS 
 
 
   Anaplastic thyroid carcinoma (ATC) is one of the most lethal human 
neoplasia and the absence of active therapies is the major impediment to the 
successful control of the disease. 
In this study I have proposed a novel therapeutic approaches based on the use 
of oncolytic adenoviruses and in particular of a second-generation adenoviral 
mutant, dl922-947. I showed that dl922-947 had a greater cytopathic effect 
with respect to dl1520, an oncolytic virus already in clinical trials and dl922-
947 showed also a superior efficiency with respect to dl1520 against ATC 
tumour xenografts. These data suggest that dl922-947 could represent a better 
option for virotherapy of ATC with respect to dl1520. 
It is well known that the successful application of therapeutic strategies based 
on replicating oncolytic viruses is limited by several obstacles and the major 
one is the incomplete viral dissemination within tumour mass. Since it has been 
suggested that vascular remodelling or normalization of tumour vessels 
induced by anti-angiogenic treatment could improve the delivery of viruses to 
tumour cells, in this study I have proposed a therapeutic strategy based on the 
use of Bevacizumab, a recombinant humanized monoclonal antibody to the 
VEGF, in combination with dl922-947. The results of experiments showed that 
the combined treatment Bevacizumab plus dl922-947 enhanced the 
antineoplastic effects of the virus against ATC xenografts. Moreover, the 
analysis of viral distribution performed treating animals bearing KAT-4 tumour 
xenografts with Bevacizumab and then injecting the AdGFP within the tumour, 
confirmed that Bevacizumab pre-treatment improved the distribution within the 
tumour since a more intense GFP staining was observed in all tumour tissues. 
Finally the data obtained treating in vitro KAT-4 cells with Bevacizumab and 
dl922-947, indicated that the effects of inhibition of tumour xenografts growth 
were not due to a direct activity on ATC cells but to a direct activity on tumour 
stroma. 
In conclusion, the results described in this study encourage the use of the 
dl922-947 virus for new therapeutic protocols for the treatment of ATC and in 
particular a combination between the virus and anti-angiogenic treatment could 
represent a better option for virotherapy against this very aggressive carcinoma. 
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Anaplastic thyroid carcinoma (ATC) is one of the most ag-
gressive solid tumors and shows morphological features of a
highly malignant, undifferentiated neoplasm. Patients with
ATC have a poor prognosis with a mean survival time of 2–6
months; surgery, radiotherapy, and chemotherapy do not im-
prove survival. Gene therapy approaches and oncolytic vi-
ruses have been tested for the treatment of ATC. To enhance
the antineoplastic effects of the oncolytic adenovirus dl1520
(Onyx-015), we treated ATC cells with lovastatin (3-hydroxy-
methylglutaryl-CoA reductase inhibitor), a drug used for the
treatment of hypercholesterolemia, which has previously
been reported to exert growth-inhibitory and apoptotic ac-
tivity on ATC cells. Lovastatin treatment significantly in-
creased the effects ofdl1520 againstATCcells. The replication
of dl1520 in ATC cells was enhanced by lovastatin treatment,
and a significant increase of the expression of the early gene
E1A 13 S and the late gene Pentonwas observed in lovastatin-
treated cells. Furthermore, lovastatin treatment significantly
enhanced the effects of dl1520 against ATC tumor xenografts.
Lovastatin treatment could be exploited to increase the effi-
cacy of oncolytic adenoviruses, and further studies are war-
ranted to confirm the feasibility of the approach in ATC
patients. (Endocrinology 148: 5186–5194, 2007)
THYROID NEOPLASIAS INCLUDE well-differentiatedfollicular and papillary carcinomas, poorly differenti-
ated papillary and follicular carcinomas, and undifferenti-
ated anaplastic carcinomas (1).
Anaplastic carcinoma (ATC) constitutes 1–7% of all thy-
roid cancer cases. It arises from thyroid follicular cells show-
ing morphological features of a highly malignant, undiffer-
entiated neoplasm with multiple atypical mitotic figures; it
reveals no follicular structures, colloid formation, or other
features of thyroid differentiation (2). p53 and -catenin mu-
tations are the genetic alterations most frequently found in
poorly differentiated and anaplastic carcinomas (3).
ATC represents one of the most aggressive human ma-
lignancies because it invariably has a fatal prognosis. In fact,
the absence of active therapies is themajor impediment to the
successful control of the disease (2–4). Therefore, novel ther-
apeutic approaches are required.
Selective replication oncolytic viruses represent a novel
therapeutic approach; adenovirus and other viruses have
been engineered for selective replication within neoplastic
cells. Themost common approach is the deletion of viral gene
whose product is necessary for replication in normal cells but
expendable in cancer cells. Unfortunately, due to the mul-
tifunctional nature of many viral proteins, the gene deletion
approach for viral selective replication frequently results in
a reduced replication and therapeutic potency (5).
The first replication-competent adenoviral mutant de-
scribed, dl1520 (Onyx-015), contains a deletion of E1B-55K,
which inhibits p53 and prevents apoptosis, allowing dl1520
replication in cancer cells lacking functional p53 pathway but
not in normal cells. dl1520 was expected to replicate selec-
tively in a high percentage of human cancers being the p53
pathway nonfunctional in about 50% of human neoplasia.
However, the role of p53 in determining dl1520 selectivity
has remained controversial for years because it was shown
that dl1520 can replicate in tumor cell lines retaining wild-
type p53 sequences, and its replication in primary cells is not
restricted by p53.
Recently it has been shown that E1B-55K mediates late-
viral RNA transport, and dl1520 tumor-selective replication
is determined by a unique property of tumor cells to effi-
ciently export late viral RNA in the absence of E1B-55K. Thus,
loss of E1B-55K-mediated late viral RNA export, rather than
p53 degradation, is the major determinant of dl1520 selective
replication in neoplastic cells (5).
The use of dl1520 oncolytic virus as monotherapy has
demonstrated limitations in efficacy, making more research
necessary for the design of strategies that will increase its
tumor-eradicating potential (6).
dl1520 has been used in conjunction with chemotherapeu-
First Published Online August 9, 2007
Abbreviations: AdGFP, GFP-transducing adenovirus; ATC, anaplas-
tic thyroid carcinoma; CAR, coxsackievirus-adenovirus receptor; Ct,
cycle threshold; FACS, fluorescence-activated cell sorter; FITC, fluores-
cein isothiocyanate; GFP, green fluorescent protein; HEK, human em-
bryonic kidney; MEK,MAPK kinase; MOI, multiplicity of infection; pfu,
plaque-forming unit.
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tic agents in clinical trials with evidence for potential syn-
ergistic antitumor activity. The use of dl1520 in conjunction
with cisplatin and 5-fluorouracil has been examined in a
phase II clinical trial involving head and neck carcinoma
patients. dl1520 has been used in combination with leucov-
orin and 5-fluorouracil in a phase II trial in patients with
gastrointestinal carcinoma metastatic to the liver and with
gemcitabine in a phase I/II trial in patients with unresectable
pancreatic carcinoma (6, 7). All these studies have shown that
combined treatment with dl1520 and chemotherapy in-
creases the therapeutic effects.
We previously demonstrated an antineoplastic activity of
dl1520 against ATC cell lines; however, high multiplicity of
infections (MOIs) were used (8). Synergistic cell killing ef-
fects of dl1520 with doxorubicin or paclitaxel were observed
in ATC cell lines, with the IC50 drug values reduced 1.75- to
11-fold in the presence of dl1520 (8). We have also shown
increased efficacy of dl1520 followed by ionizing radiations,
compared with either treatment alone (9). These data, pre-
viously obtained by us, suggest that dl1520 may be a valid
tool in the treatment of anaplastic thyroid carcinoma in com-
bination with other agents.
To develop novel therapeutic strategies based on replica-
tion selective adenoviruses, it is important to identify drugs
able to enhance the oncolytic activity. In the present study,
we evaluated the effects of lovastatin in combination with
dl1520 against ATC cells.
Lovastatin (3-hydroxy-methylglutaryl-CoA reductase in-
hibitor), a drug used for the treatment of hypercholesterol-
emia, has been reported to exert growth-inhibitory activity in
vitro and in vivo. Farnesyl- and geranylgeranylpyrophos-
phate, intermediates in the cholesterol synthetic pathway,
are needed for isoprenylation, a crucial step for membrane
attachment of cellular proteins like Ras, Rho, Cdc42, Rac, etc.
(10, 11). By inhibiting protein isoprenylation, lovastatin in-
duces a reduction of cell proliferation and apoptosis (10–11).
Moreover, it has been demonstrated that low doses of lova-
statin induce apoptosis of ATC cells (12, 13).
We have observed that lovastatin significantly enhanced
the antineoplastic activity of dl1520 against ATC cells and its
replication. Furthermore, a significant increase in viral gene
expression was induced by lovastatin in ATC cells. Finally,
the combined treatment induced a significant reduction of
the growth of ATC tumor xenografts.
Materials and Methods
Cell lines and preparation of adenoviruses
The human anaplastic thyroid carcinoma cell lines used in the study
are ARO, FRO, KAT-4, and Cal 62.
ARO and FRO human thyroid anaplastic carcinoma cell lines were
established by Dr. G. J. Juillard (Department of Radiation Oncology,
University of California, Los Angeles, Los Angeles, CA), and ARO and
FRO cell lines were kindly provided by Professor J. A. Fagin (University
of Cincinnati College of Medicine, Cincinnati, OH). KAT-4 cells were
obtained from Dr. Ain (University of Kentucky, Lexington, KY). Cal 62
cell line was obtained from Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH (Braunschweig, Germany), German Collection
of Microorganisms and Cell Cultures.
The NPA line derives from poorly differentiated papillary carcinoma
and was obtained by Dr. G. J. Juillard. The FB1 cell line derives from a
follicular carcinoma (14). Human embryonic kidney (HEK)-293 cells
were obtained from American Type Culture Collection (Manassas, VA).
KAT-4 cells harbor amutated p53 gene, (273Arg-His), whereas FRO
cells express very low levels of p53, but no p53 gene mutation was
observed (8).
Cells were grown in DMEM supplementedwith 10% fetal calf serum,
glutamine, and ampicillin/streptomycin.
dl1520 (ONYX-015), a gift from Dr. A. Balmain (Cancer Research
Institute, University of California, San Francisco, CA) and Dr. I. Ganly
(Memorial Sloan-Kettering Cancer Center, New York, NY), is a chimeric
human group C adenovirus (Ad2 and Ad5) that has a deletion between
nucleotides 2496 and 3323 in the E1B region that encodes the 55-kDa
protein. In addition, there is a C to T transition at position 2022 in region
E1B that generates a stop codon at the third codon of the protein. Viral
stocks were expanded in the HEK-293 cell line and purified, as previ-
ously reported (8).
Stocks were stored at 70 C after the addition of glycerol to a con-
centration of 50% (vol/vol). Virus titer was determined by plaque-
forming units (pfu) on the HEK-293 cells.
Adenovirus infection
Cells were detached, counted, and plated in 6-well plate at 70% cell
density. After 24 h, cells were infected with a green fluorescent protein
(GFP)-transducing adenovirus (AdGFP), a nonreplicating E1 and E2-
deleted adenovirus encoding GFP, diluted in growth medium at dif-
ferent MOIs; medium was replaced after 2 h. Cells were washed 24 h
after infection and then trypsinized, washed, and resuspended in 300 l
PBS and analyzed for GFP expression on a fluorescence-activated cell
sorter (FACS) cytometer (Dako Cytomation, Carpinteria, CA) and Sum-
mit version 4.3 software (Dako, Carpinteria, CA).
Different treatment conditions were used for the evaluation of lova-
statin effects: antineoplastic effects were evaluated in the presence of
lovastatin, whereas experiments designed to evaluate the effects of the
drug on the early phases of viral infection were performed with a short
treatment time.
For the evaluation of lovastatin effects on adenoviral entry and GFP
expression, the cells were treated for 16 hwith 10m lovastatin and then
infected for 24 h with AdGFP. Cells were harvested and prepared for
FACS analysis as previously described.
For the evaluation of the cytoxic effects of the dl1520 virus, 1  103
cells were seeded in 96-well plates, and 24 h later lovastatin was added
to the incubation medium. After an additional 16 h, medium was re-
placed with a medium containing or not lovastatin plus dl1520 at dif-
ferent MOIs. After 14 d the cells were fixed with 10% trichloroacetic acid
and stained with 0.4% sulforhodamine B in 1% acetic acid (15). The
bound dye was solubilized in 200 l of 10 mm unbuffered Tris solution,
and the optical density was determined at 490 nm in amicroplate reader
(Bio-Rad Laboratories, Mu¨nchen, Germany). The percent of survival
rates of treated cells were calculated by assuming the survival rate of
untreated cells to be 100%.
Quantitative PCR of dl1520
To quantify the amount of dl1520 virus genome on lovastatin treat-
ment, ATC cells were treated with 10 m lovastatin for 16 h and then
media replaced with a medium containing different MOIs of dl1520
alone orwith lovastatin. After 24 h of infection, cell mediawere collected
and viral DNA extracted using a QIAamp DNA minikit (QIAGEN,
Valencia, CA). Viral DNA was then quantified by real-time PCR using
assay-specific primer and probe. A real-time-based assaywas developed
using the following primers: 5-GCCACCGAGACGTACTTCAGC-
CTG-3 (upstream primer) and 5-TTG TAC GAG TAC GC G GTA
TCCT-3 (downstream primer) for the amplification of 143 bp sequence
of the viral hexon gene (from bp 99 to 242 bp). For quantification, a
standard curve was constructed by assaying serial dilutions of dl1520
virus ranging from 0.1 to 100 pfu.
To quantify the amount of dl1520 virus genome in tumor xenografts,
total DNA was extracted from 20 mg of each sample using a DNA
purification system (Promega Corp., Madison, WI). DNA was resus-
pended in 200 l of water and 2 l used for the real-time PCR-based
assay. For each experiment the DNA was extracted from three different
samples of each treatment group.
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Quantitative RT-PCR of dl1520 gene expression
Cells were infected with 10 or 100 pfu of dl1520, in the presence or in
the absence of 10 m of lovastatin, and harvested at 24 h after infection.
Cells were dissolved in 1 ml Trizol (Invitrogen, Carlsbad, CA). RNA
quality was evaluated by agarose gel electrophoresis; DNase treatment
was performed. One microgram of total RNA was reverse transcribed
and the expression of E1A 13 S and Penton genes monitored using
real-time PCR with the following specific primers: E1A 13 S forward,
5-AATGGCCGCCAGTCTTTT-3 and reverse, 5-ACACAGGACTG-
TAGACAA-3; Penton forward, 5-TAACCAGTCACAGTCGCAAG-3
and reverse, 5-CCCGCGCCTTAAACTTATT-3 (16). To calculate the
relative expression levels, we used the 2[][]cycle threshold (Ct)
method. Negative controls, samples without RT-PCR, or CDNA tem-
plate were included in every PCR run, always resulting negative (data
not shown).
Detection of cell surface coxsackievirus-adenovirus receptor
(CAR) receptor
Cells were grown in six-well plates. After 48 h cells were detached in
PBS-EDTA 10 mm, washed with PBS, and then incubated 1.5 h in FACS
buffer with a mouse anti-CAR monoclonal antibody RmcB (1:250) (17).
After washing, the cells were incubated in FACS buffer containing the
secondary antibody conjugated to fluorescein isothiocyanate (FITC) (1:
100; Sigma, St. Louis, MO) and analyzed for CAR expression on a Cyan
cytometer (Dako Cytomation) and Summit version 4.3 software (Dako).
Human thyroid tissue samples and real time RT-PCR
Normal and neoplastic human thyroid tissues were obtained from
surgical specimens and immediately frozen in liquid nitrogen. Thyroid
tumors were collected at the Laboratoire d’Histologie et de Cytologie,
Centre Hospitalier (Lyon Sud, France) and the Laboratoire d’Anatomie
Pathologique, Hospital de L’Antiquaille (Lyon, France).
Total RNAwas isolated and DNase digested using the RNeasy mini-
kit (QIAGEN) according to the manufacturer’s recommendations. One
microgramof total RNA fromeach samplewas reverse transcribedusing
random hexamers as primers andMoloney leukemia virus reverse tran-
scriptase (Applied Biosystems, Foster City, CA) to yield cDNA.
To design a quantitative PCR assay, a human ProbeLibray system
(Exiqon, Vedbaek, Denmark) was used. Probe and primers pair to am-
plify a fragment for real-time PCR of Cxadr mRNA were selected en-
tering its accession number (NM001338.3) on the assay design page of
the ProbeFinder software. ProbeFinder generated an intron-spanning
assay identifying the exon-exon boundarieswithin submitted transcript.
An amplicon of 93 nucleotides scattered among sixth and seventh exon
was selected. The primer sequences were: Cxadr forward, 5-AT-
GAAAAGGAAGTTCATCAACGTA-3, Cxadr reverse, 5-AATGAT-
TACTGCCGATGTAGCTT-3. The same procedure was used to select
probe and primes for housekeeping gene G6PDH, accession no. X03674.
The primer sequences were: G6PDH forward, 5-ACAGAGTGAGC-
CCTTCTTCAA-3, G6PDHreverse, 5-GGAGGCTGCATCATCGTACT-
3. All fluorigenic probes were dual labeled with FAM at 5end andwith
a black quencer at the 3end.
Relative quantitative TaqMan RT-PCR was performed in a Chromo4
detector (MJ Research, Waltham, MA) in 96-well plates using a final
volume of 25 l. The conditions used for PCR were 10 min at 95 C and
then 45 cycles of 20 sec at 95 C and 1 min at 60 C. Each reaction was
performed in duplicate. To calculate the relative expression levels, we
used the 2[][]Ct method, where [][]Ct []Ct,sample []Ct,reference.
Written informed consent was obtained from all participants. The
study protocol was approved by the ethics committees of the Centre
Hospitalier Lyon Sud and the University Federico II, Napoli, and con-
ducted in accordance with the principles of the Declaration of Helsinki
as revised in 2000.
Protein extraction and Western blot analysis
In all experiments 70% confluent cells were used. Cells were homog-
enized directly into lysis buffer (50 mm HEPES, 150 mm NaCl, 1 mm
EDTA, 1 mm EGTA, 10% glycerol, 1% Triton X-100, 1 mm phenylmeth-
ylsulfonyl fluoride, 1 g/ml aprotinin, 0.5 mm sodium orthovanadate,
20 mm sodium pyrophosphate). The lysates were clarified by 20 min
centrifugation at 14,000  g. Protein concentrations were estimated by
a Bio-Rad assay, and then proteins were boiled in Laemmli buffer [Tris-
HCl (pH 6.8) 0.125 m, sodium dodecyl sulfate 4%, glycerol 20%, 2-mer-
captoethanol 10%, bromophenol blue 0.002%] for 5 min before electro-
phoresis. Proteins were subjected to SDS-PAGE (10% polyacrylamide)
under reducing conditions. After electrophoresis, proteins were trans-
ferred to nitrocellulose membranes (Immobilon; Millipore Corp., Bil-
lerica, MA); complete transfer was assessed using prestained protein
standards (Bio-Rad, Hercules, CA). After blocking with Tris-buffered
saline-BSA [25 mm Tris (pH 7.4), 200 mmNaCl, 5% BSA], the membrane
was incubated with the primary polyclonal rabbit antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) against CAR receptor SC-15–405 (1:200)
for 1 h (at room temperature) or with the monoclonal antibody against
against-actin (Sigma).Membraneswere then incubatedwith the horse-
radish peroxidase-conjugated secondary antibody (1:10,000) for 45 min
(at room temperature), and the reaction was detected with an ECL
system (Amersham Life Science, Buckinghamshire, UK).
Tumorigenicity assay
Experiments were performed with 6-wk-old female athymic mice
(Charles River, Calco, Lecco, Italy). FRO cells (4 106) were injected into
the right flank of 80 athymic mice. After 20 d, when tumors were clearly
detectable, the animals were divided into four groups (20 animals/
group), and tumor volume was evaluated. Two groups received lova-
statin in the drinking water (40 mg/1000 ml) and after 6 d dl1520 (5 
107 pfu) was injected in the peritumoral area in a group treated with
lovastatin and in an untreated group.
Tumor diameters were measured with calipers every second day by
two blind and neutral observers until the animals were killed. Nomouse
showed signs of wasting or other indications of toxicity. Tumor volumes
were calculated by the formula of rotational ellipsoid: Tumor volume
A B2/2, where A is the axial diameter and B is the rotational diameter.
All mice were maintained at the Dipartimento di Biologia e Patologia
Cellulare e Molecolare Animal Facility. The animal experimentations
described hereinwere conducted in accordancewith accepted standards
of animal care and in accordance with the Italian regulations for the
welfare of animals used in studies of experimental neoplasia, and the
study was approved by our institutional committee on animal care.
The amount of lovastatin administered was chosen considering that
the average daily water intake for each mouse was 5–7.5 ml and 10
mg/kg/d was the best dose of lovastatin for obtaining biological effects
in mice.
To evaluate the genome equivalent copies of dl1520 in tumor xeno-
grafts, three animals bearing FRO xenografts received lovastatin in the
drinking water (40 mg per 1000 ml). After 6 d, dl1520 (5  107 pfu) was
injected in the peritumoral area of the mice treated with lovastatin and
in three untreated mice.
After 48 h animals were killed, tumors excised, DNA extracted, and
viral replication evaluated by real-time PCR. DNAquality was analyzed
by real-time PCR of the -actin gene.
Statistical analysis
Comparisons among different treatment groups in the experiments
in vivo were made by the ANOVA method and the Bonferroni post hoc
test using a commercial software (Prism 4; GraphPad, San Diego, CA).
Assessment of differences among rate of tumor growth in mice was
made for each time point of the observation period; treatment groups
were control, dl1520, lovastatin, and lovastatin plus dl1520.
The analysis of the cell-killing effect in vitro was also made by the
ANOVA method and the Bonferroni post hoc test. For all the other
experiments, comparisons among groups were made by the ANOVA
method and t test.
Results
Analysis of adenoviral infectivity of human thyroid
carcinoma cell lines
To evaluate the susceptibility of ATC cells to adenoviral
infection, we infected a panel of thyroid carcinoma cell lines
using an AdGFP; the results are shown in Fig. 1A.
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The anaplastic thyroid carcinoma cell linesARO, FRO, and
KAT-4 display the lowest percentage of fluorescent cells at
all the MOIs used; indeed 100 pfu/cell are required to obtain
greater than 50% ARO- and KAT-4-positive cells, whereas at
10 pfu/cell, about 50% of FRO cells are positive. Conversely,
follicular thyroid carcinoma cell line FB1 and papillary thy-
roid carcinoma cell line NPA showed about 90% of GFP-
positive cells at 10 MOI. As a positive control HEK-293 cells
were used.
Because adenoviral infection occurs via the attachment to
the CAR (18), we analyzed CAR expression by Western blot;
two CAR-specific bands of 44 and 46 kDa, respectively, were
detected in all the samples (Fig. 1B). However, certain dif-
ferences were observed in their levels; in ATC cell lines,
variable levels ranging from very low to intermediate were
observed; the papillary thyroid carcinoma-derived NPA cell
line, the follicular carcinoma-derived FB-1 cell lines, and the
ATC-derived KAT-4 cell line express the highest CAR levels.
A cytofluorimetric analysis was performed to evaluate the
presence of CAR on the cell membrane (Fig. 1C), showing the
absence of CAR on the cell surface in FRO, NPA, Cal 62, and
FB1 cells. This observation suggests a CAR-independent en-
try of AdGFP in these cell lines. The cell lines ARO and
KAT-4 showed the presence of CAR on the cell membrane
despite being the less susceptible to adenoviral infection.
To confirm that anaplastic thyroid carcinomas express low
levels of CAR, we evaluated the CAR mRNA levels in human
thyroid carcinoma tissuesbyRT-PCR. Significantly lower levels
(**, P  0.01) in CAR gene expression were observed in pap-
illary carcinomas, follicular carcinomas, and anaplastic thyroid
carcinomas with respect to normal thyroid samples (Fig. 2).
Lovastatin enhances the cell killing effects and the
replication of the oncolytic adenovirus dl1520
Because our data show that ATC are not readily infected
by therapeutic adenoviruses, we decided to evaluate the
effects of lovastatin in combination with dl1520. KAT-4 cells
were chosen as representative of ATC cells at low sensitivity
to the infection with dl1520; the FRO cell line was chosen as
representative of an intermediate infectivity (8, 9).
In both cell lines, the combined treatment enhanced the
cell-killing activity of dl1520. In FRO cells treated with 10
pfu/cell of dl1520, an additive and significant (2.5 m) and
FIG. 1. A, Percentage of positive cells upon AdGFP infection. Cells were infected at different MOIs with AdGFP, and after 24 h the percentage
of fluorescent cells was evaluated by FACS analysis. ATC cell lines ARO and KAT-4 were the less sensitive to AdGFP infection at all MOIs
used, whereas FRO and Cal 62 cells displayed a higher percentage of GFP-expressing cells. FRO cells showed about 50% of GFP-positive cells
at 10 MOI; conversely, Cal 62 at the same MOI showed about 80% of positive cells. Follicular thyroid carcinoma cell line FB1 and papillary
thyroid carcinoma cell line NPA showed about 90% of GFP-positive cells at 10 MOI. HEK-293 cells were used as a positive control. The data
are the mean of three different experiments; the bar represents the SD. B, Western blot analysis of CAR expression in thyroid carcinoma cell
lines. Cal 62, FRO, and ARO cells showed low expression of total CAR levels, whereas FB1, KAT-4, and NPA cells expressed the higher of total
CAR levels. Equal amounts of protein lysates (50 g) were loaded. C, Cytofluorimetric analysis of CAR expression on the membrane of thyroid
carcinoma cell lines. Flow cytometry analysis showed the absence of cell surface CAR expression in FRO, NPA, Cal 62, and FB1 thyroid cancer
cell lines. ARO and KAT-4 cell lines showed the presence of CAR on the membrane. HEK-293 cells were used as positive control. Cells were
incubated with a anti-CAR (RmcB) monoclonal antibody or FITC-labeled mouse alone. In all experiments, 70% confluent cells were used.
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highly significant (5m) increase in cell killingwas observed.
In KAT-4 cells a highly significant increase in cell killing was
induced by lovastatin treatment at all MOIs and lovastatin
concentrations used (Fig. 3A).
Next, we quantified the amount of dl1520 virus genome by
real-time PCR in FRO and KAT-4 cells untreated, treated
with lovastatin for 16 h (lovastatin 16 h) before infection, or
kept in the presence of lovastatin after the infection (lova-
statin) and infected with different MOIs. In FRO cells at 10
pfu/cell, both lovastatin treatments induced an highly sig-
nificant (**, P  0.01) increase in viral replication (Fig. 3B).
KAT-4 cells kept in the presence of lovastatin also showed a
highly significant increase in viral replication (**, P  0.01),
whereas 16 h treatment did not modify viral replication.
Lovastatin enhances the expression of viral genes
Because ATC cells infected in the presence of lovastatin
show an increase in viral replication, we decided to evaluate
the infectivity of ATC cells in the presence of lovastatin.
KAT-4 and FRO cells were pretreated with a noncytotoxic
concentration of lovastatin (10 m) for 16 h and then infected
with AdGFP at different MOIs. FACS analysis of treated or
untreated cells showed that lovastatin treatment induced a
highly statistically significant (**, P  0.01) increase in the
number positive cells ranging from 3 up to 10% (Fig. 4A).
Both cell lines showed a strong increase in fluorescence to
cell ratio on lovastatin treatment (Fig. 4A).
Pharmacological inhibitors of the Raf-MAPK kinase
(MEK)-ERK pathway up-regulates CAR expression on the
cell surface of cancer cells (19); lovastatin is a well-known
inhibitor of p21 Ras isoprenylation and activity. Therefore,
we evaluated the effects of lovastatin on CAR expression in
FIG. 2. CAR expression in thyroid carcinoma tissues. Three normal
thyroid samples (1–3), eight anaplastic (4–11), two follicular (12 and13),
and four papillary (14–17) thyroid carcinomas were used for real-time
RT-PCRanalysis ofCARexpression, showinga reduction inCARmRNA
levels in all neoplastic tissues with respect to normal thyroid samples.
FIG. 3. A,Lovastatin treatment enhances the cell-killing effects of the oncolytic adenovirusdl1520.FROandKAT-4 cellswere treatedwith lovastatin
and then infectedwith the oncolytic adenovirus dl1520 at differentMOIs. In FRO cells kept in the presence of lovastatin, a highly significant increase
(**,P 0.01) in the cell-killing activity of 10 pfu/cell of dl1520was observed in associationwith 5M of lovastatin. In KAT-4 cells kept in the presence
of 1 and 2.5 M of lovastatin, a highly significant increase (**, P  0.01) of the cell-killing activity in combination with 1 and 2.5 pfu/cell of dl1520
wasobtained.Viral concentrationable to induce thesamecell-killing in the twocell lineswereused.Thedataareexpressedaspercentagesofuntreated
control cells andare themeanof five different experiments; thebar represents the SD.B,Lovastatin treatment enhances the replication of the oncolytic
adenovirus dl1520. FROandKAT-4 cells were treatedwith lovastatin (10M) for 16 h and then infectedwith amedium containing dl1520 (lovastatin
16 h) or dl1520 plus lovastatin (lovastatin). FRO cells at 10 pfu/cell showed a highly significant increase (**, P  0.01) of dl1520 replication in both
groups. KAT-4 cells at 5 and 10 pfu/cell showed a highly significant increase (**, P 0.01) of dl1520 replication only in the group kept in the presence
of lovastatin. The data are the mean of three different experiments; the bar represents the SD.
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ATC cells. CAR levels on cell surface, evaluated by FACS
analysis (Fig. 4B), were not modified by lovastatin treatment.
Because lovastatin-treated cells showed an increased in flu-
orescence to cell ratio, we hypothesized that lovastatin treat-
ment could enhance viral gene expression. To monitor the ex-
pression of adenoviral genes in lovastatin-treatedATC cells we
selected two adenoviral genes, whose expression is correlated
with different stages of the adenoviral life-cycle: E1A 13 S rep-
resenting genes transcribed from the immediate early region
and Penton representing genes expressed from the late region.
FRO and KAT-4 cells were infected respectively with a
MOI of 100 and 10 pfu of dl1520 in the presence or in the
absence of lovastatin (10 m). The expression levels of E1A
13 S and Penton gene were measured by real-time RT-PCR at
24 h. Cotreatment with lovastatin significantly (*, P  0.05)
enhanced the expression levels of E1A 13 S and Penton gene
in both cell lines (Fig. 5).
Lovastatin in combination with dl1520 reduces the growth
of ATC tumor xenografts
To demonstrate that the combined treatment lovastatin
and dl1520 could potentially yield improved clinical efficacy,
we evaluated the effects of lovastatin treatment in vivo.
FRO cells were injected into the right flank of athymic mice,
and after 20 d, when tumors were clearly detectable (T  0),
animals were randomized into four groups and lovastatin was
added in the drinking water of two groups. The animals re-
ceived lovastatin until the end of the experiment. After 6 d
dl1520 was injected within the tumor (T  6), twice per week.
In Fig. 6A, tumorgrowth is expressed as apercentage of growth
relative to the volume observed at T  0.
dl1520 treatmentwas able to significantly reduce (*,P 0.05)
the growth of tumor xenografts in the initial phase of the treat-
ment (up to T  30). Conversely, the combination lovastatin
plus dl1520was able to induce a highly significant reduction (**,
P  0.01) in tumor growth until the end of experiment, con-
firming that lovastatin enhances the antineoplastic effects of
dl1520. No toxicities were observed in treated animals.
Finally, we evaluated by real-time PCR (Fig. 6B) the genome
equivalent copiesofdl1520 inanimalsbearingFROxenograftsand
treated with dl1520 and dl1520 plus lovastatin. Lovastatin treat-
ment was able to induce a 10-fold increase in viral replication.
Discussion
ATC represents one of the most lethal human neoplasia
being refractory to conventional therapies, including sur-
FIG. 4. A, Percentage of GFP-positive cells and fluorescence to cell ratio in lovastatin-treated cells. FRO and KAT-4 cells were treated with 10 M
of lovastatin for 16 h and then infected with AdGFP at different MOIs. FACS analysis was performed 24 h after the infection. Lovastatin increased
the percentage of AdGFP-positive KAT-4 and FRO cells (upper panel). Highly significant difference between treated and untreated cells is observed
in both cell lines starting from 10 pfu/cell point. Lovastatin-treated cells showed an increase in fluorescence to cell ratio (lower panel). The difference
is statistically high (P  0.01), starting from 25 pfu/cell (FRO cells) or 50 pfu/cell (KAT-4 cells).The data are the mean of five different experiments;
the bar represents the SD.B, Lovastatin does notmodifyCARexpression on the cell surface ofKAT-4 andFROcells.KAT-4 andFROcellswere treated
with 10M lovastatin for 16 h and then incubatedwith anti-CAR (RmcB)monoclonal antibody (lovastatin) and comparedwith untreated control cells
(control). Background emission was assessed by incubating KAT-4 and FRO cells with FITC-labeled mouse alone (FITC). CAR expression was not
modified by lovastatin treatment. The data are representative of three different experiments.
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gery, radioactive iodine, and chemotherapy (2–4). Develop-
ment and evaluation of novel treatment strategies are
needed.
Replication-selective oncolytic viruses (virotherapy) are
being developed as a novel, targeted form of anticancer treat-
ment. dl1520 (Onyx-015) was the first virus that had been
genetically engineered for replication-selectivity for treat-
ment in cancer patients. Recent results from a phase III clin-
ical trial have confirmed the ability of an oncolytic adeno-
virus (H101) bearing an E1B-55kD gene deletion similar to
that present in dl1520 to increase the response rate of naso-
pharyngeal carcinoma in combination with cisplatin (20).
Selective oncolytic replicating adenoviruses have been
tested inATC cell lines and tumor xenografts showing prom-
ising results (8, 9); however, high MOIs of dl1520 were re-
quired to efficiently kill ATC cells.
The efficacy of oncolytic adenoviruses as therapeutic
agents relies on the capability of target neoplastic cells to
bind, internalize, and sustain the replication of adenoviruses.
We analyzed the infectivity of a panel of human thyroid
carcinoma cell lines, showing a low infectivity in most ATC
cell lines. Conversely, papillary or follicular thyroid carci-
noma cells display a higher infectivity. In a previous study,
we evaluated the infectivity of ATC cell lines ARO, KAT-4,
and FRO infecting the cells for 48 h with a lacZ-transducing
adenovirus and evaluating the percentage of infected cells
counting stained cells in randomly selected fields. The dif-
ferent results obtained in the two studies can be explained
with the use of different reporter genes, infection times, and
detection techniques.
Adenovirus internalization relies on the presence of cell
surface of the CAR; a Western blot analysis has been per-
formed on total cell lysates showing discrete or high expres-
sion levels of CAR.However, cytofluorimetric assay for CAR
expression on cell surface showed a low or absent expression
of CAR, suggesting a CAR-independent adenoviral entry in
thyroid carcinoma cells lines. Furthermore, a significant re-
duction in CAR gene expression was observed in anaplastic
FIG. 6. Tumor growth delay induced by lovastatin and dl1520. A, Relative tumor growth of animals treated with dl1520 and lovastatin and
control groups. Lovastatin treatment alone did not show statistically significant differences with the untreated control, whereas dl1520 induced
a statistically significant reduction (P  0.05) in the initial phase of the treatment (up to T  30). The combination of dl1520 plus lovastatin
significantly delayed tumor growth, compared with dl1520 single treatment group from T  36 (P  0.01). Data are presented as mean  SD.
B, Genome equivalent copies in tumor xenografts. A 10-fold increase in genome equivalent copies in tumor xenografts excised from lovastatin
plus dl1520 group was observed. The data are the mean of three different experiments; the bar represents the SD.
FIG. 5. Lovastatin increases viral gene
expression in ATC cells. FRO and KAT-4
cells were treated with 10 M of lovastat-
in; after 16 h cells were infected with
dl1520. For FRO cells a MOI of 100 pfu
was used; KAT-4 cells were infected with
10 pfu. After 24 h the levels of expression
of the adenoviral immediate early region
gene E1A 13 S and the adenoviral of late
region gene Penton were measured by
real-time RT-PCR. Lovastatin treatment
significantly enhanced the expression
levels of theE1A 13 S and Penton gene. In
FRO cells a 4-fold increase of E1A 13 S
expression levels and 16-fold increase of
Penton gene were obtained. In KAT-4
cells, a 5-fold increase of E1A 13 S ex-
pression levels and 12-fold increase in
Penton expression levels were observed.
The data are the mean of three different
experiments; the bar represents the SD.
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thyroid carcinomas samples, compared with normal thyroid
tissues.
Our observations are in agreement with previous studies
and confirm a low susceptibility of ATC cells to therapeutic
approaches based on adenoviral vectors (21).
It is worth noting that CAR expression is negatively reg-
ulated by TGF- during the switch from epithelial to mes-
enchymal phenotype, and human pancreatic carcinoma cells
show loss of epithelial differentiation and CAR surface lo-
calization on TGF- treatment (22). In ATC cell lines, we
observed discrete or high total expression levels of CAR and
loss of surface localization of CAR. Our results indicate that
the loss of thyroid differentiation, a typical feature of ATC,
causes an intracellular localization of CAR receptor, proba-
bly by increasing the recycling of CAR receptors or shifting
them to the cytosol.
BecauseATC cells display a low infectivity and a highMOI
of dl1520 is required to efficiently kill these cells, we decided
to enhance the oncolytic activity by using lovastatin in com-
bination with dl1520.
Lovastatin, a drug used for the treatment of hypercholes-
terolemia, has previously been reported to exert growth-
inhibitory activity in vitro and in vivo. Farnesyl- and gera-
nylgeranylpyrophosphate, intermediates in the cholesterol
synthetic pathway, are needed for isoprenylation a crucial
step for membrane attachment of cellular proteins like of p21
Ras, Rho, Cdc42, Rac, etc. (10). By inhibiting protein isopre-
nylation, lovastatin exerts its cellular effects, including a
reduction of cell proliferation and induction of apoptosis
(10). It is worth noting that low doses of lovastatin induce
apoptosis or differentiation of ATC cells (11, 12).
Our study demonstrates that the treatment of ATC cell
lines KAT-4 and FRO with lovastatin significantly increased
the effects of dl1520.
A significant increase in viral replication was observed in
lovastatin-treated cells. In FRO cells a significant increase
was observed infecting lovastatin-treated cells with 10 pfu/
cell, whereas at 1 pfu/cell, no significant differences were
observed. In KAT-4 cells kept in the presence of lovastatin
and infected with 5 or 10 pfu/cell, significant increase was
observed; however, the pretreatment with lovastatin for 16 h
was not able to increase viral replication.
These results suggest that the increase in viral replication
observed treating ATC cells with lovastatin is viral dose or
lovastatin treatment time dependent. Therefore, it is possible
that higher MOIs of dl1520 in combination with a 16-h lo-
vastatin pretreatment could result in enhanced viral repli-
cation in KAT-4 cells.
Increased infection efficacy could account for the increased
oncolytic activity after lovastatin treatment; moreover, lova-
statin inhibits the isoprenylation and the activity of p21 ras,
blocking MEK activity, and it has been reported that MEK
inhibitors, U0126 and PD184352, increase the expression of
CAR protein and adenoviral entry in cancer cells (19). There-
fore, we evaluated the adenoviral entry and CAR expression
levels in ATC cell lines treated with lovastatin. We observed
a modest, albeit significant, increase in adenoviral entry (3–
10%), which that it is not sufficient to explain the effects of
lovastatin on viral replication and cell survival.
CAR expression levels either total (data not shown) or on
the cell surface were not modified by lovastatin treatment.
Cholesterol deprivation of FRO and KAT-4 cells did not
modify adenoviral entry (data not shown), suggesting that
the effects of lovastatin were not mediated by the inhibition
of cholesterol synthesis.
It has been shown that lovastatin inhibits the invasiveness
of an ATC cell line (ARO) and focal adhesion kinase phos-
phorylation, a nonreceptor tyrosine kinase playing a crucial
role in integrin-mediated cell adhesion (23); therefore, it is
not possible to exclude that lovastatin induces changes in
integrin pattern on cell surface. Because it has been suggested
that integrins can act as a coreceptor for adenovirus types 2
and 5 (24), the modest increase in adenoviral entry observed
by us could be due to changes in integrins pattern induced
by lovastatin. Further studies are required to verify this
hypothesis.
A high increase in the fluorescence to cell ratio of lovas-
tatin-treated cells was observed. This observation suggested
to us that the drug could enhance the expression of viral
genes, thereby increasing viral replication. To confirm this
hypothesis, the expression of two viral genes, representing
the early and the late phases, was analyzed in ATC cells
infected with dl1520. Lovastatin increased significantly the
expression of early gene E1A 13 S and a late gene Penton.
It has been proposed that drugs able to affect the cell cycle
could enhance viral oncolysis by modulating viral gene ex-
pression (25). Lovastatin together with other clinically used
statins (fluvastatin and simvastatin) induces a G1 arrest of
prostate cancer cells (26). A block of the cell cycle inATC cells
could enhance viral gene expression and increase the repli-
cation of dl1520. Further studies are required to clarify the
mechanisms responsible for the effects of lovastatin on dl1520
gene expression and replication.
The administration of lovastatin per os to nude mice bear-
ing ATC tumor xenografts enhances the antitumoral effects
of dl1520 and increases the viral replication in vivo, confirm-
ing that this treatment could improve the clinical efficacy of
replicating oncolytic adenoviruses. Interestingly, the injec-
tion of lovastatin and the virus within the tumor did not
increase the effects of dl1520 (data not shown), indicating that
a constant lovastatin blood concentration should be obtained
to enhance the effects of dl1520.
The data presented here identify lovastatin as a promising
agent for increasing the effects of oncolytic adenoviruses in
ATC cells. It has been reported that FR901228 and trichos-
tatin A, members of a new group of anticancer agents, the
histone deacetylase inhibitors (27–29), or the MEK inhibitors
U0126 and PD184352 (18) increase the antineoplastic effects
of oncolytic adenoviruses. However, these agents have been
used in a limited number of clinical trials, whereas 3-hy-
droxy-3-methylglutaryl coenzyme A reductase inhibitors
have been widely used to reduce cardiovascular diseases
withoutmajor adverse effects (10, 11). Lovastatin is generally
well tolerated; the most important adverse effect is myotox-
icity within the first 3 months of therapy (11). The risk of
muscle dysfunction is increased by coadministration of other
drugs able to interfere with lovastatin metabolism (11).
In the present study, in in vitro experiments, lovastatinwas
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used at final concentrations ranging from 2.5 to 10 m, and
in in vivo,we used a lovastatin concentration of 10mg/kg/d.
Although the therapeutic dose for the treatment of hyper-
cholesterolemia is about 1 mg/kg/d, which yields serum
levels of 0.1 m, it has been shown that serum concentrations
of 2–4 m of lovastatin are well tolerated in animal models,
and clinical trials of phase I and II have been performedusing
25 mg/kg/d with encouraging results (11). All these data
indicate that lovastatin at a dose of 10 mg/kg/d could prob-
ably be used in ATC patients in combination with dl1520
without major side effects.
In conclusion, we have identified lovastatin as a drug that
increases adenoviral replication and enhances the effects of
an oncolytic adenovirus in vitro and in vivo against ATC cells.
Therefore, lovastatin could be useful in the context of gene
therapy for anaplastic thyroid carcinoma. Further studies are
required to confirm the feasibility of this approach in ATC
patients.
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